Warfarin

On this page

Quick Reference

RxDrug of choiceWarfarin for mechanical heart valves and antiphospholipid syndrome; DOACs preferred for non-valvular AF and VTE.

AltAlternativesApixaban, rivaroxaban, edoxaban, dabigatran for AF/VTE; LMWH for pregnancy and cancer.

⊘AvoidPregnancy (except mechanical valves), active bleeding, recent CNS/eye surgery, intracranial hemorrhage, cerebral aneurysm, dissecting aorta, pericarditis, bacterial endocarditis, malignant hypertension, hypersensitivity.

DxTest of choiceINR (international normalized ratio) for monitoring; consider VKORC1/CYP2C9 genotyping for dose prediction.

ScKey scoreCHA2DS2-VASc for AF stroke risk; HAS-BLED for bleeding risk; TTR for quality of anticoagulation.

→When to referMechanical heart valves, APS, recurrent thrombosis, TTR <60%, complex drug interactions, pregnancy with mechanical valves.

Warfarin is a high-risk, high-reward anticoagulant requiring meticulous monitoring; it remains irreplaceable for mechanical valves and APS, but DOACs are safer for most other indications.

Warfarin is a vitamin K antagonist anticoagulant that remains essential for mechanical heart valves and antiphospholipid syndrome despite the advent of DOACs. It requires individualized dosing based on genetics, age, and comorbidities, with routine INR monitoring to maintain a narrow therapeutic window (target INR 2.0-3.0 for most indications). Initiate at 5 mg daily (2.5-3 mg for sensitive populations), overlap with heparin for acute thrombosis, and adjust based on INR response. Major bleeding occurs at ~3% per year, with intracranial hemorrhage accounting for half; manage over-anticoagulation with vitamin K and prothrombin complex concentrate. Drug interactions are extensive, especially with amiodarone, paracetamol, and carbamazepine, requiring proactive monitoring. Time in therapeutic range (TTR) >65% is the key quality metric.

Overview and Recommendations

Key Facts

•Warfarin is a vitamin K antagonist that inhibits VKORC1, blocking recycling of vitamin K and thereby preventing γ-carboxylation of clotting factors II, VII, IX, X and proteins C and S, rendering them inactive. This mechanism underlies its use for VTE, AF, mechanical heart valves, and post-MI thromboembolism reduction.
•Despite DOACs offering fixed dosing and superior safety (lower intracranial hemorrhage and all-cause mortality), warfarin remains the only oral anticoagulant approved for mechanical heart valves and is indispensable for antiphospholipid syndrome (APS), where DOACs have shown excess thrombotic events in triple-positive patients.
•Warfarin has a narrow therapeutic index with dose requirements ranging from 0.5 mg to >20 mg daily, driven by genetic polymorphisms: VKORC1 -1639G>A explains ~30% of variability (AA genotype requires ~50% lower dose), CYP2C9*2/3 explains ~12%, and CYP4F2 V433M explains 5-7%. CYP2C93/*3 carriers have a 21.8-fold hazard for over-anticoagulation during initiation.
•The anticoagulant effect is delayed: onset within 24 hours but peak at 72-96 hours because factor II (prothrombin) has a 60-hour half-life. Early INR rise is from factor VII (half-life 4-6 hours) and does not reflect antithrombotic protection. The early drop in protein C (half-life ~8 hours) creates a transient procoagulant state, mandating heparin bridging for acute thrombosis.
•Warfarin's origins trace to spoiled sweet clover causing hemorrhagic disease in cattle in the 1920s; it was developed as a rodenticide before therapeutic use in 1954. Its low cost, long track record, and reversibility with vitamin K and PCC keep it relevant for patients with severe renal impairment (CrCl <15 mL/min) and in resource-limited settings.

Clinical Use

•Suspect need for warfarin in patients with venous thromboembolism (DVT/PE), atrial fibrillation with CHA2DS2-VASc ≥2 (men) or ≥3 (women), mechanical heart valves (especially mitral or older-generation aortic), antiphospholipid syndrome with thrombosis, or left ventricular thrombus.
•Assess for absolute contraindications: active bleeding, recent CNS or eye surgery, intracranial hemorrhage, cerebral aneurysm, dissecting aorta, pericarditis, bacterial endocarditis, threatened abortion, eclampsia, malignant hypertension, or hypersensitivity.
•Order baseline CBC, LFTs, and INR. Consider genotyping for VKORC1 and CYP2C9 to identify patients at risk for extreme dose requirements (≤21 mg/week or ≥49 mg/week).
•Determine target INR: 2.0-3.0 for most indications (VTE, AF, mechanical aortic valve with bileaflet and sinus rhythm); 2.5-3.5 for mechanical mitral valve, caged ball/caged disk valves, or high-risk APS.
•Initiate warfarin at 5 mg daily for first 1-2 days; use 2.5-3 mg in elderly (≥65 years), Asian patients, those with heart failure or hepatic impairment, or known VKORC1 AA genotype. For acute thrombosis, overlap with heparin/LMWH for ≥5 days and until INR therapeutic for 2 consecutive days.
•Plan bridging with LMWH for high thromboembolic risk procedures (mechanical mitral valve, recent VTE <3 months, AF with prior stroke). For low-risk patients, hold warfarin 5 days before surgery without bridging.
•Educate patients about consistent dietary vitamin K intake, potential drug interactions (amiodarone, paracetamol >2 g/day, antibiotics, carbamazepine, metformin), and signs of bleeding or thrombosis.
•Monitor INR daily/every other day during initiation until therapeutic for two consecutive measurements, then weekly, then every 2-4 weeks once stable. Aim for time in therapeutic range (TTR) >65%.
•Consider alternative anticoagulants: DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred for non-valvular AF and VTE due to lower intracranial hemorrhage and all-cause mortality. Reserve warfarin for mechanical valves, APS, severe renal impairment, or when DOACs are contraindicated.
•For cancer-associated VTE, DOACs are preferred over warfarin due to lower bleeding risk; warfarin remains an option when DOACs are contraindicated. In APS, warfarin is standard; DOACs are contraindicated due to increased thrombotic risk.

Safety

•Initiate warfarin at 5 mg daily for most patients; reduce to 2.5-3 mg in elderly, Asian, or VKORC1 AA carriers. Use pharmacogenetics-guided algorithms (e.g., WRAPID) to reduce over-anticoagulation risk.
•Titrate dose based on INR: for subtherapeutic INR (<2.0), increase dose by 10-20%; for INR 3.1-4.0, hold 1-2 doses and reduce dose by 10-20%; for INR 4.0-5.0 without bleeding, hold and consider vitamin K 1-2.5 mg oral; for INR >5.0 without bleeding, hold and give vitamin K 2.5-5 mg oral; for INR >5.0 with major bleeding, hold, give vitamin K 10 mg IV, and administer PCC (25-50 U/kg) or FFP (15 mL/kg).
•Monitor INR at least daily during initiation, then weekly until stable, then every 2-4 weeks. Extend to every 6-8 weeks for patients with consistently stable INRs over months. Use self-testing only in motivated patients with stable control and training.
•Avoid concomitant NSAIDs, antiplatelet agents (aspirin, clopidogrel, prasugrel), SSRIs, and other anticoagulants unless absolutely necessary. If combined, monitor closely for bleeding.
•Manage drug interactions proactively: when starting amiodarone, reduce warfarin dose by ~25% and recheck INR within one week. For paracetamol >2 g/day, anticipate INR rise and monitor within 3-5 days. For carbamazepine initiation, expect warfarin dose increase of ~50% and monitor INR weekly.
•Reverse warfarin for life-threatening bleeding: vitamin K 10 mg slow IV plus PCC (25-50 U/kg) or FFP (15 mL/kg). For non-major bleeding with INR >5.0, give vitamin K 2.5-5 mg oral and hold warfarin until INR <5.0.
•Refer patients with mechanical heart valves, APS, or recurrent thrombosis to a specialized anticoagulation clinic. Consider referral for patients with TTR <60% despite good adherence.
•Discharge patients with clear instructions: carry medication card, report signs of bleeding (unusual bruising, dark stools, hematuria, hematemesis), avoid new medications without consulting, maintain consistent vitamin K intake.
•For pregnant women with mechanical heart valves, use warfarin only if dose <5 mg daily to minimize fetal risk; otherwise, consider LMWH with anti-Xa monitoring. Warfarin is contraindicated in pregnancy for all other indications.
•In pediatric patients, dose based on age and body surface area; use LMWH preferentially in young children due to easier monitoring. Monitor INR frequently using pediatric-specific algorithms.
•For patients with APS, be aware that lupus anticoagulant may interfere with INR measurement; consider using chromogenic factor Xa assay or a PT reagent less sensitive to lupus anticoagulant for monitoring.
•Do not use warfarin in severe hepatic impairment (Child-Pugh C); use LMWH instead. In renal impairment (CrCl <15 mL/min), warfarin is preferred over DOACs but requires close monitoring.
•When restarting warfarin after a bleeding event, ensure the cause of bleeding is addressed and INR <5.0 before resuming. Consider a lower starting dose and more frequent monitoring.

Board Review — High Yield

•VKORC1 -1639G>A, AA genotype requires ~50% lower warfarin dose; highest frequency in East Asians (~90%).
•CYP2C9*3, Reduces S-warfarin clearance by ~80%; homozygous carriers have 21.8-fold hazard for over-anticoagulation.
•Factor II half-life 60 hours, Explains 72-96 hour delay to peak effect; early INR rise from factor VII is not antithrombotic.
•Protein C decline, Early drop creates transient procoagulant state; heparin bridging required for acute thrombosis.
•Warfarin-induced skin necrosis, Rare (<0.1%), occurs within days, associated with protein C deficiency; discontinue warfarin.
•Amiodarone interaction, Reduces warfarin dose requirement by ~25%; monitor INR within one week.
•Paracetamol >2 g/day, Causes clinically significant INR rise (mean increase 1.2); often overlooked.
•Anticoagulation-related nephropathy, AKI with INR >3.0 without other cause; hold warfarin and correct INR.
•Fiix-PT monitoring, Measures only factors II and X; reduces thromboembolism by 56% vs standard PT-INR.
•TTR >65%, Associated with lower thromboembolism and bleeding; TTR <60% warrants investigation.

Deep Dive — Evidence Details

Introduction and Chemical Structure

▸Warfarin is a racemic 4-hydroxycoumarin that inhibits VKORC1, blocking vitamin K-dependent clotting factor synthesis.
▸Approved by the FDA in 1954, it remains the only oral anticoagulant indicated for mechanical heart valves.
▸Its narrow therapeutic window, numerous drug interactions, and need for INR monitoring make it a high-risk medication requiring careful oversight.

HY High Yield: The S-enantiomer of warfarin is 2-5 times more potent than the R-enantiomer, which explains why CYP2C9 polymorphisms (which primarily metabolize S-warfarin) have a major impact on dose requirements [11].

Warfarin — Warfarin, sold under the brand name Coumadin among others, is used as an anticoagulant medication. It is commonly used to prevent deep vein thrombosis...Wikipedia ↗

Warfarin is a vitamin K antagonist anticoagulant that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and is used for the prophylaxis and treatment of venous thromboembolism (VTE), thromboembolic complications associated with and cardiac valve replacement, and reduction of recurrent myocardial infarction and stroke after MI [label].

Also Called

Warfarin sodium, Coumadin, Jantoven
Vitamin K antagonist (VKA)
4-hydroxycoumarin

Chemical Identity

Warfarin sodium, USP, is a racemic mixture of the R- and S-enantiomers of 3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium salt, crystallized as an isopropanol clathrate (molecular weight 330.31) [label]. It appears as a white, odorless, crystalline powder that is discolored by light, very soluble in water, freely soluble in alcohol, and very slightly soluble in chloroform and ether [label]. The S-enantiomer is approximately 2-5 times more potent than the R-enantiomer in inhibiting vitamin K epoxide reductase (VKORC1) ^[11]^D5.

History and Clinical Context

Warfarin’s origins trace to a mysterious hemorrhagic disease of cattle in the 1920s, later linked to spoiled sweet clover containing dicoumarol ^[7]^D5. The compound was synthesized and developed as a rodenticide before being repurposed as a therapeutic anticoagulant; it received initial U.S. approval in 1954 [label]^[7]^D5. Despite the advent of direct oral anticoagulants (DOACs), warfarin remains the only oral anticoagulant approved for mechanical heart valves [label] and is a cornerstone in antiphospholipid syndrome and other conditions where DOACs are suboptimal or contraindicated ^[22]^D5. Its narrow therapeutic index, numerous drug-food interactions, and requirement for routine international normalized ratio (INR) monitoring demand a thorough understanding of its pharmacokinetics and pharmacodynamics, which are detailed in the sections that follow.

Pearl: Though DOACs have replaced warfarin for many indications, warfarin remains the only oral anticoagulant approved for mechanical heart valves and is indispensable for patients with antiphospholipid syndrome who require a target INR of 2.0-3.0 (or higher in high-risk subsets) [label]^[22]^D5.

Mechanism of Action

▸Warfarin inhibits VKORC1, blocking regeneration of reduced vitamin K and preventing γ-carboxylation of clotting factors II, VII, IX, X and proteins C and S.
▸Peak anticoagulant effect is delayed 72-96 hours due to the 60-hour half-life of factor II, creating a window for heparin bridging.
▸The S-enantiomer is 2-5 times more potent than R-warfarin and is metabolized by CYP2C9, linking pharmacogenetics to dose requirements.

HY High Yield: The early fall in protein C (half-life ~8 hours) creates a transient hypercoagulable state; always bridge with heparin when initiating warfarin for acute thromboembolism.

From the chemical structure, the pharmacologic cascade begins at the molecular target: warfarin inhibits the C1 subunit of vitamin K epoxide reductase (VKORC1), the enzyme that recycles oxidized vitamin K epoxide back to its reduced form [label]. This blockade disrupts the vitamin K cycle, starving the liver of the reduced vitamin K cofactor required for the post-ribosomal γ-carboxylation of glutamic acid residues on clotting factor precursors ^[42]^D5. Without γ-carboxylation, factors II, VII, IX, and X, and the endogenous anticoagulant proteins C and S, cannot bind calcium or assemble on phospholipid surfaces, rendering them biologically inactive [label].

Onset and Time Course

Warfarin does not affect pre-circulating factors; anticoagulation begins only as existing functional factors are cleared. An effect is detectable within 24 hours, but peak anticoagulation is delayed 72 to 96 hours because factor II (prothrombin), with the longest half-life of 60 hours, must be depleted [label]. The half-lives of the affected proteins dictate the sequence: factor VII (4-6 hours) falls first, followed by protein C (~8 hours), factor IX (24 hours), protein S (~30 hours), factor X (48-72 hours), and finally factor II [label]. The early drop in protein C, a natural anticoagulant, creates a transient procoagulant state during the first 24-48 hours, which is why bridging is recommended when initiating warfarin in acute thrombosis [label].

Duration of Action

A single dose of racemic warfarin exerts effects lasting 2 to 5 days, consistent with the cumulative clearance of the vitamin K-dependent factors [label]. With daily dosing, the effects of successive doses overlap, and steady-state anticoagulation is reached after approximately 5-7 days, reflecting the time needed to achieve equilibrium between synthesis inhibition and factor turnover [label].

Stereoselectivity

The drug is administered as a racemic mixture of R- and S-enantiomers. The S-enantiomer is 2 to 5 times more potent than the R-enantiomer in humans and is primarily metabolized by the polymorphic CYP2C9 enzyme [label]. This stereoselective potency explains why genetic variants in CYP2C9 disproportionately affect S-warfarin clearance and, consequently, anticoagulant response ^[43]^B2b.

Pearl: Because warfarin's anticoagulant effect lags behind its plasma concentration, peaking days after the drug is cleared, dose adjustments based on a single INR must account for the 72- to 96-hour delay to steady-state effect; chasing an elevated INR with a dose reduction on day 2 risks overcorrection when factor II finally falls.

Half-Lives of Vitamin K-Dependent Proteins

Protein	Half-Life (hours)	Role
Factor VII	4-6	Procoagulant
Protein C	~8	Anticoagulant
Factor IX	24	Procoagulant
Protein S	~30	Anticoagulant
Factor X	48-72	Procoagulant
Factor II (prothrombin)	60	Procoagulant

Resistance and Pharmacogenomics

▸VKORC1 -1639G>A explains ~30% of warfarin dose variability; CYP2C9*2/*3 adds ~12%; CYP4F2 V433M adds ~5%.
▸Pharmacodynamic warfarin resistance is caused by missense mutations in VKORC1 (e.g., Asp36Tyr, Val66Met) and is more common in patients requiring >20 mg/day.
▸Genotype-guided dosing reduces major bleeding by ~50% (RR 0.47, NNT 67) but does not consistently improve TTR versus a clinical algorithm; race-stratified algorithms are recommended.

HY High Yield: In patients requiring warfarin doses >20 mg/day, check for VKORC1 missense mutations (e.g., Asp36Tyr), these patients are pharmacodynamically resistant and may require extreme doses or alternative agents.

! Warning: Do not use a pharmacogenetic algorithm developed in European populations for African-ancestry patients without including CYP2C9*5, *6, *8, *11 and rs12777823, failure to do so may worsen anticoagulation control [32,41].

The interindividual variability in warfarin dose requirement, ranging from 0.5 mg to over 20 mg daily, is driven primarily by genetic polymorphisms in the drug's metabolic and target pathway. Understanding these variants is essential for safe initiation, especially in populations with high allele frequencies for warfarin-sensitizing or warfarin-resistance variants.

Key Genetic Variants Influencing Warfarin Dose

VKORC1 - the pharmacodynamic target. The -1639G>A (rs9923231) promoter polymorphism is the single most important predictor of warfarin dose, explaining approximately 30% of dose variability ^[43]^B2b. The minor A allele creates a suppressor E-box binding site, reducing VKORC1 expression and increasing warfarin sensitivity ^[35]^D5. Carriers of the AA genotype require about 50% lower doses than GG homozygotes ^[52]^C4. The -1639A allele frequency varies by ancestry: ~90% in East Asians, ~40% in Europeans, and ~10% in Africans ^[35]^D5^[45]^B2b.

CYP2C9 - the metabolic gateway. CYP2C92 (rs1799853, Arg144Cys) and CYP2C93 (rs1057910, Ile359Leu) reduce enzyme activity by ~30% and ~80%, respectively, and together explain 12% of dose variability ^[43]^B2b. Homozygous CYP2C9*3/3 carriers have a hazard ratio of 21.8 for over-anticoagulation during initiation (95% CI 9.46-50.42) ^[43]^B2b. In African-ancestry populations, additional reduced-function alleles, CYP2C95, *6, *8, *11, must be considered because they are absent in Europeans ^[41]^B2b^[53]^C4.

CYP4F2 - the vitamin K metabolism modifier. The V433M polymorphism (rs2108622) exerts a gene‑dose effect: each Val433 allele increases warfarin dose requirement by about 4 mg/week ^[34]^B2b. In a linear regression model, CYP4F2 contributes an additional 5-7% to dose variability beyond CYP2C9 and VKORC1 ^[34]^B2b^[56]^C4. The PharmVar consortium now defines 17 star alleles for CYP4F2, facilitating standardized reporting ^[62]^D5.

African‑ancestry‑specific variants. The SNP rs12777823 in the CYP2C cluster is associated with a 12-15% lower dose requirement in African Americans, independent of CYP2C9*2/*3 ^[41]^B2b. An expression quantitative trait locus (eQTL), rs4889606, which modulates VKORC1 expression, was also associated with a 1.1 mg/day increase in dose requirement in African Americans ^[55]^C4.

Gene	Variant(s)	Effect on warfarin dose	Explained variance	Special populations
VKORC1	-1639G>A (rs9923231)	Dose ↓ 30-50% per A allele	~30%	Highest frequency in East Asians
CYP2C9	2 (rs1799853), 3 (rs1057910)	Dose ↓ 20-30% per variant allele	~12%	5, 6, 8, 11 in African ancestry
CYP4F2	V433M (rs2108622)	Dose ↑ 4 mg/week per Val allele	5-7%	-
CYP2C cluster	rs12777823 (African ancestry)	Dose ↓ 12-15%	~3%	African Americans

Warfarin Resistance (Pharmacodynamic)

True pharmacodynamic resistance, failure to achieve therapeutic INR despite high serum warfarin concentrations (>2.3 mg/L), is rare but clinically important. Missense mutations in VKORC1 that alter the warfarin-binding pocket are the most common cause ^[76]^C4. In a cohort of 289 patients requiring >20 mg/day, 10% had serum warfarin concentrations consistent with pharmacodynamic resistance; of those, 53% carried VKORC1 mutations, including p.Asp36Tyr, p.Val66Met, p.Val54Leu, and p.Leu128Arg ^[76]^C4. The Asp36Tyr variant is particularly prevalent in Ethiopian Jews (15%) and Ashkenazi Jews (4%) and is associated with a mean dose of 80 mg/week ^[75]^B3b. Cell-based assays show that these mutations increase the warfarin IC₅₀ by up to 199-fold (for phenprocoumon) and that resistance is mutation-specific, with warfarin showing less resistance variation than other coumarins ^[74]^D5^[77]^D5.

Pharmacogenomics‑Guided Dosing: Clinical Evidence and Controversies

Two large randomized trials tested genotype-guided versus clinical-only dosing. The EU-PACT trial (n=455) used a pharmacogenetic algorithm for the first 5 days and found a higher percentage of time in therapeutic range (TTR) at 12 weeks: 67.4% vs 60.3% (adjusted difference 7.0 percentage points, 95% CI 3.3-10.6; P<0.001) and a shorter median time to therapeutic INR (21 vs 29 days; P<0.001) ^[33]^A1b. In contrast, the COAG trial (n=1015) compared a pharmacogenetic algorithm to a clinical algorithm and found no difference in TTR at 4 weeks (45.2% vs 45.4%; P=0.91), with a significant interaction by race (P=0.003) suggesting worse outcomes in black patients ^[32]^A1b. The key difference: EU-PACT used a fixed-dose control, whereas COAG used a clinical algorithm control, making the incremental benefit of genotype information less apparent ^[38]^D5.

A meta-analysis of 9 RCTs (n=2812) demonstrated a 53% reduction in major bleeding with genotype-guided dosing (RR 0.47, 95%; NNT = 67 to prevent one major bleed) ^[37]^A1a. The ENGAGE AF- 48 genetic substudy (n=14,348) confirmed that CYP2C9/VKORC1 genotype bins identify patients at increased bleeding risk on warfarin: sensitive and highly sensitive responders had HRs of 1.31 and 2.66, respectively, for early bleeding, and derived greater safety benefit from compared with warfarin (p<sub>interaction</sub>=0.0066) ^[36]^A1b.

Controversies and Guideline Disagreement

Question	Position A (EU-PACT, meta-analysis)	Position B (COAG trial)	Strength	Implication
Does genotype-guided dosing improve TTR?	Yes, +7% vs fixed dose ^[33]^A1b	No, 0% vs clinical algorithm ^[32]^A1b	Moderate	Benefit depends on comparator; greatest when fixed-dose is standard
Is genotype-guided dosing cost-effective?	Yes, in LMICs (ICER ~₹35,962/QALY) ^[60]^A1b	Uncertain in high-income settings ^[50]^A1a	Moderate	7 of 16 cost-effectiveness analyses found cost-saving ^[50]^A1a
Should race be used in algorithms?	Race-stratified algorithms outperform race-combined ^[41]^B2b	Race interaction may harm black patients ^[32]^A1b	Weak	Use population-specific algorithms (e.g., including rs12777823 for African ancestry)

Pearl: Genotype-guided warfarin dosing reduces major bleeding by approximately 50% (RR 0.47) compared with clinical-only dosing, but the improvement in time in therapeutic range is inconsistent and depends on whether the control is a fixed-dose or a clinical algorithm, preemptive genotyping of CYP2C9, VKORC1, and CYP4F2 is most clinically useful in patients with high likelihood of extreme dose requirements (≤21 mg/week or ≥49 mg/week) ^[37]^A1a^[49]^B3b.

Pharmacokinetics (LADME)

▸Warfarin is completely absorbed orally, 99% protein-bound, and almost entirely hepatically metabolized via CYP2C9 (S-enantiomer) and CYP1A2/CYP3A4 (R-enantiomer).
▸The effective half-life averages 40 hours (range 20-60 hours), requiring 5-7 days to reach steady state; renal impairment does not significantly alter clearance.
▸Genetic variants in CYP2C9 and VKORC1, along with age and drug interactions (e.g., CYP2C9 inhibitors), are the main drivers of interindividual PK variability.

HY High Yield: Because S-warfarin has 2-5 times more anticoagulant activity than R-warfarin and is metabolized by CYP2C9, any drug that inhibits CYP2C9 (e.g., amiodarone, fluconazole, capecitabine) will disproportionately increase the anticoagulant effect and require dose reduction.

The genetic and pharmacodynamic resistance factors described in the preceding section directly shape the pharmacokinetic (PK) behavior of warfarin, a drug whose absorption, distribution, metabolism, and excretion together explain its narrow therapeutic index and the need for individualized dosing. The following LADME framework provides the PK foundation that governs every clinical decision from initiation to maintenance and perioperative .

Absorption

Warfarin sodium is essentially completely absorbed after oral administration, with peak plasma concentrations reached within the first 4 hours [label]. Food delays absorption but does not reduce the extent; bioequivalence studies in healthy Chinese subjects showed that the geometric mean ratio of Cmax under fed versus fasting conditions was 100.62% (90% CI within 90.00%-111.11%) ^[100]^A1b. For patients receiving enteral feeding tubes, caution is warranted: approximately 20.8% of studies report reduced stability or bioavailability for warfarin when administered via feeding tubes, influenced by tube material and preparation methods ^[93]^D5.

Distribution

Warfarin has a volume of distribution of about 0.14 L/kg, and approximately 99% is bound to plasma proteins, primarily albumin [label]. This high protein binding means that hypoalbuminemia (common in critical illness, malnutrition, or liver disease) can increase the free fraction and potentiate anticoagulation. Displacement interactions (e.g., with sulfonamides, ) can transiently elevate unbound drug, though the clinical impact is often mitigated by increased clearance of the free drug.

Metabolism

Elimination of warfarin is almost entirely by hepatic metabolism [label]. Warfarin is a racemic mixture of S- and R-enantiomers. The S-enantiomer possesses 2 to 5 times greater anticoagulant activity than the R-enantiomer but is cleared more rapidly [label]. S-warfarin is predominantly metabolized by CYP2C9 (a polymorphic enzyme), while R-warfarin is metabolized by CYP1A2, CYP3A4, and others [label]. Patients with variant CYP2C9 alleles (e.g., *2, *3) have significantly reduced S-warfarin clearance, leading to lower dose requirements and increased bleeding risk ^[39]^D5[label]. The CYP2C9-mediated pathway is a common site of drug-drug interactions: coadministration of CYP2C9 inhibitors (e.g., , , ) can increase S-warfarin exposure. A study with capecitabine showed persistent elevation of a CYP2C9 substrate (celecoxib) for at least 7 days after capecitabine discontinuation, implying similar prolonged interaction with warfarin ^[97]^C4. Conversely, CYP2C9 inducers (e.g., ) accelerate clearance. Other drugs studied for PK interaction with warfarin include henagliflozin (no clinically relevant effect, GMRs for AUC within 80-125% ^[89]^C4), sonidegib (no effect on S- or R-warfarin PK ^[90]^C4), guselkumab (no effect on CYP2C9 activity in psoriasis patients ^[91]^C4), BI 425809 (no effect on CYP2C9 ^[96]^C4), and DAV132 (colon-targeted adsorbent, no effect on warfarin PK ^[92]^A1b).

Excretion

The terminal half-life of warfarin after a single dose is approximately 1 week, but the effective half-life ranges from 20 to 60 hours, with a mean of about 40 hours [label]. The half-life of R-warfarin is longer (37 to 89 hours) than that of S-warfarin (21 to 43 hours) [label]. Up to 92% of an orally administered dose is recovered in urine, almost entirely as inactive metabolites; very little unchanged drug is excreted [label]. Renal impairment does not significantly affect warfarin clearance, but it may increase bleeding risk due to uremic platelet dysfunction and concurrent comorbidities.

Special Populations and PK Variability

Geriatric: Patients 60 years or older exhibit greater INR response to warfarin, likely due to a combination of pharmacokinetic and pharmacodynamic factors. Limited data suggest a slight decrease in R-warfarin clearance in the elderly, but no difference in S-warfarin clearance [label].

Pediatric: While limited warfarin-specific pediatric PK data are available, studies of the related VKA acenocoumarol in children (median age 8.9 years) showed that body surface area and indication explained 45.0% of dose variability; adding VKORC1 and CYP2C9 genotypes increased this to 61.8% ^[98]^B2b. These principles likely apply to warfarin.

Hepatic impairment: Because warfarin is hepatically metabolized, liver disease can prolong the half-life and increase sensitivity. No specific dose modifications are provided in the label, but careful monitoring is required.

Pharmacokinetic Summary Table

Parameter	Value	Reference
Oral bioavailability	~100%	[label]
Time to peak concentration	4 h	[label]
Volume of distribution	0.14 L/kg	[label]
Plasma protein binding	99%	[label]
Terminal half-life (single dose)	~1 week	[label]
Effective half-life (range)	20-60 h (mean 40 h)	[label]
S-warfarin half-life	21-43 h	[label]
R-warfarin half-life	37-89 h	[label]
Primary metabolic enzyme (S-warfarin)	CYP2C9	[label]
Primary metabolic enzymes (R-warfarin)	CYP1A2, CYP3A4, CYP2C19	[label]
Urinary excretion (metabolites)	Up to 92%	[label]
Urinary excretion (unchanged)	Negligible	[label]

These PK properties explain the delayed onset of action (anticoagulation within 24 hours, peak effect at 72-96 hours) and the prolonged duration of effect (2-5 days for a single dose) [label]^[85]^D5. The narrow therapeutic window combined with interindividual variability in clearance, driven by genetics, age, comorbidities, and drug interactions, makes routine INR monitoring mandatory. The pharmacodynamic consequences of warfarin’s PK profile are explored in the next section.

Pearl: When initiating warfarin, the effective half-life of 40 hours means that steady-state is not reached for 5-7 days; therefore, dose adjustments based on early INR (before day 3-4) may be misleading and should be made cautiously, especially in patients with CYP2C9 variants or interacting medications [label]^[39]^D5.

Pharmacodynamics

▸Peak anticoagulant effect is delayed 72-96 hours despite rapid absorption, because warfarin suppresses synthesis of existing clotting factors that must be cleared naturally.
▸The early INR rise (days 1-2) reflects factor VII suppression (half-life 4-6 hours) and does not represent full antithrombotic effect; true protection requires reduction of factors II and X (half-lives 60 and 48-72 hours, respectively).
▸Warfarin is a tight-binding competitive inhibitor of VKORC1 with nanomolar inhibition constant and stoichiometric binding; the dose-response curve is directly governed by VKORC1 expression level, explaining the large impact of the -1639G>A polymorphism.

HY High Yield: Do not equate an early therapeutic INR (day 1-2) with antithrombotic protection. The INR at that point reflects factor VII suppression only; full protection requires reduction of factors II and X, which takes 72-96 hours.

From the pharmacokinetic profile, the pharmacodynamic effect of warfarin reflects the sequential suppression of vitamin K-dependent clotting factors and the inherent anticoagulant proteins C and S. An anticoagulation effect generally occurs within 24 hours after oral administration, but peak anticoagulant effect is characteristically delayed 72 to 96 hours [label]. This lag persists despite near-complete absorption within 4 hours because warfarin inhibits the synthesis of functional clotting factors through competitive, tight-binding inhibition of the C1 subunit of vitamin K epoxide reductase (VKORC1) ^[147]^D5, and the decline in circulating factor activity depends on the natural clearance of existing factors. The duration of action from a single dose of racemic warfarin is 2 to 5 days [label], corresponding to the elimination half-lives of the suppressed factors.

Time Course of Anticoagulation and Factor Suppression

The onset and magnitude of the INR rise are driven by the shortest-lived factor. Factor VII, with a half-life of only 4 to 6 hours, falls rapidly, producing an early INR increase within 24 to 48 hours [label]. However, this early INR rise does not reflect a full antithrombotic effect, because the antithrombotic state requires suppression of factors II (half-life 60 hours) and X (half-life 48 to 72 hours). The Fiix trial demonstrated that a monitoring method sensitive only to factors II and X (Fiix-PT) reduced thromboembolic events compared with standard PT-INR monitoring (1.2% vs 2.3% per patient-year; RR 0.52, 95% CI 0.25-1.13; p<sub>non-inferiority</sub> <0.0001), confirming that early transient factor VII suppression contributes to INRs that are misleadingly high relative to true antithrombotic intensity ^[111]^A1b.

Vitamin K-Dependent Protein	Half-Life (hours)	Clinical Implication
Factor VII	4-6	Earliest INR rise; not antithrombotic
Protein C	~8	Early decline may create transient procoagulant state
Protein S	~30	Contributes to loss of anticoagulant balance
Factor IX	24	Intermediate suppression
Factor X	48-72	Key contributor to sustained antithrombotic effect
Factor II (prothrombin)	60	Most prolonged suppression; full antithrombotic effect requires its reduction

Inhibitory Kinetics and Potency

Warfarin is a tight-binding competitive inhibitor of VKORC1, acting at nanomolar concentrations ^[147]^D5. The inhibition constant is in the low nanomolar range, and drug binds stoichiometrically: once all VKORC1 molecules are occupied, additional warfarin constitutes “free” drug that does not further suppress factor synthesis ^[147]^D5. This stoichiometric relationship explains why small changes in VKORC1 expression, governed by the VKORC1 -1639G>A promoter polymorphism, directly shift the dose-response curve ^[43]^B2b^[147]^D5. The S-enantiomer of warfarin possesses 2 to 5 times greater anticoagulant activity than the R-enantiomer in humans [label], consistent with its higher affinity for VKORC1 and its preferential clearance by CYP2C9.

Clinical Implications of the Pharmacodynamic Profile

The 72‑ to 96‑hour delay to peak effect has three practical consequences. First, loading doses are required to shorten the time to therapeutic INR, but must be balanced against the risk of excessive anticoagulation once factor II begins to decline. Second, the early decline in protein C (half-life ~8 hours) can create a transient procoagulant imbalance before factors II and X fall, particularly in patients with underlying protein C deficiency, the pathophysiologic basis for warfarin-induced skin necrosis. Third, reversal with vitamin K must account for the fact that even after the INR normalises, factor II activity remains suppressed for days; resumption of warfarin after reversal requires either a bridging strategy or a reloading schedule to avoid a period of ineffective anticoagulation.

The relative inhibitory potency of warfarin against VKORC1 is intermediate among the 4‑hydroxycoumarins; acenocoumarol and phenprocoumon are more potent in cell‑based assays ^[74]^D5. However, warfarin’s efficacy as a mixed-type inhibitor (competitive with respect to vitamin K epoxide and non‑competitive with respect to reduced vitamin K ^[74]^D5) makes it responsive to dietary vitamin K intake, a unique pharmacodynamic vulnerability that contributes to intra‑individual INR variability.

Pearl: The 72‑ to 96‑hour delay to peak effect means that an early therapeutic INR (days 1-2) is driven by factor VII decline and does not equate to antithrombotic protection, reliance on the INR alone for efficacy decisions during the first 72 hours of therapy is a common clinical trap.

Indications and Clinical Use

▸Warfarin is FDA-approved for VTE, AF, mechanical/bioprosthetic heart valves, and post-MI thromboembolic risk reduction.
▸In high-risk antiphospholipid syndrome (triple-positive), warfarin is superior to DOACs and remains standard of care.
▸DOACs have largely replaced warfarin for AF and VTE due to lower bleeding risk and mortality, but warfarin is essential for mechanical valves and severe renal impairment.

Rx Drug of Choice: Warfarin is the drug of choice for mechanical heart valves and high-risk antiphospholipid syndrome (triple-positive).

Building on the pharmacodynamic rationale of vitamin K antagonism, warfarin's clinical utility spans a defined set of thromboembolic conditions where sustained anticoagulation is required. The FDA label approves warfarin for three core indications: (1) prophylaxis and treatment of venous thrombosis and pulmonary embolism (PE); (2) prophylaxis and treatment of thromboembolic complications associated with (AF) and/or cardiac valve replacement; and (3) reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after MI [label]. Warfarin has no direct effect on an established thrombus and does not reverse ischemic tissue damage; once thrombosis has occurred, the goals are to prevent extension and secondary embolic complications [label].

Approved Indications

Venous Thromboembolism (VTE). Warfarin is indicated for the treatment of acute deep-vein thrombosis (DVT) and PE, typically following initial parenteral anticoagulation ( or low-molecular-weight heparin). The landmark Hokusai-VTE trial demonstrated that was noninferior to warfarin for recurrent VTE (3.2% vs. 3.5%; HR 0.89, 95% CI 0.70-1.13) with less bleeding ^[116]^A1b. Similarly, (2.3% vs. 2.7%; RR 0.84, 95% CI 0.60-1.18) and (2.1% vs. 3.0%; HR 0.68, 95% CI 0.44-1.04) showed noninferior efficacy with lower major bleeding rates ^[115]^A1b^[114]^A1b. Despite these data, warfarin remains a standard comparator and is still widely used when DOACs are contraindicated or unavailable.

Atrial Fibrillation. In five prospective randomized trials involving 3711 patients with non-rheumatic AF, warfarin reduced the risk of systemic thromboembolism including stroke by 60% to 86% compared with control, with major bleeding rates of 0.6% to 2.7% [label]. The BAFTA trial in patients aged ≥75 years confirmed warfarin's superiority over (yearly risk 1.8% vs. 3.8%; RR 0.48, 95% CI 0.28-0.80) without excess extracranial hemorrhage ^[187]^A1b. In the ARISTOTLE trial, apixaban was superior to warfarin for stroke/systemic embolism (1.27% vs. 1.60% per year; HR 0.79, 95% CI 0.66-0.95) with less major bleeding (2.13% vs. 3.09%; HR 0.69, 95% CI 0.60-0.80) ^[175]^A1b. ROCKET AF showed rivaroxaban noninferior to warfarin (1.7% vs. 2.2% per year; HR 0.79, 95% CI 0.66-0.96) with similar major bleeding but less intracranial hemorrhage ^[176]^A1b. RE-LY demonstrated 150 mg twice daily superior to warfarin (1.11% vs. 1.69% per year; RR 0.66, 95% CI 0.53-0.82) with similar major bleeding ^[178]^A1b. ENGAGE AF- 48 found high-dose edoxaban noninferior to warfarin (1.18% vs. 1.50% per year; HR 0.79, 97.5% CI 0.63-0.99) with less major bleeding (2.75% vs. 3.43%; HR 0.80, 95% CI 0.71-0.91) ^[113]^A1b. A meta-analysis of these four trials (71,683 patients) confirmed that DOACs reduce stroke/systemic embolism by 19% (RR 0.81, 95% CI 0.73-0.91) and all-cause mortality by 10% (RR 0.90, 95% CI 0.85-0.95) compared with warfarin ^[120]^A1a.

Mechanical and Bioprosthetic Heart Valves. Warfarin is the only oral anticoagulant approved for patients with mechanical heart valves. In a randomized trial of 254 patients with mechanical valves, warfarin alone provided a significantly greater thromboembolic-free interval than dipyridamole/aspirin (2.2 vs. 8.6 events per 100 patient-years; p<0.005) [label]. In a study comparing moderate (INR 2.65) versus high-intensity (INR 9) warfarin, thromboembolism rates were similar (4 vs. 3.7 per 100 patient-years), but major bleeding was higher in the high-intensity group (2.1 vs. 0.95 per 100 patient-years) [label]. For bioprosthetic valves, a randomized trial of 210 patients found that lower-intensity warfarin (INR 2-2.25) for 3 months post-replacement resulted in similar thromboembolism rates but fewer major hemorrhages (0% vs. 4.6%) compared with higher-intensity therapy (INR 2.5-4) [label]. Dabigatran was associated with excess thromboembolic and bleeding events in patients with mechanical valves and is contraindicated ^[180]^A1b.

Post-Myocardial Infarction. The WARIS trial (1214 patients) demonstrated that warfarin (target INR 2.8-4.8) reduced the composite of total mortality and recurrent infarction compared with placebo [label]. WARIS II (3630 patients) showed that warfarin plus aspirin reduced the composite endpoint versus aspirin alone, though at the cost of increased bleeding [label].

Off-Label and Specialized Uses

Antiphospholipid Syndrome (APS). Warfarin is the standard of care for thrombotic APS, particularly in high-risk triple-positive patients (lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I). The TRAPS trial was terminated early after rivaroxaban showed excess events (19% vs. 3%; HR 6.9, 95%) ^[104]^A1b^[197]^A1b. The RAPS trial found that rivaroxaban did not meet noninferiority for thrombin generation endpoints, though no thrombosis occurred ^[174]^A1b. Apixaban also showed increased stroke risk in APS (6/23 vs. 0/25) ^[121]^A1b. Warfarin remains the recommended anticoagulant for APS.

Left Ventricular Thrombus. A meta-analysis of 7 RCTs (554 patients) found no difference between DOACs and warfarin for thrombus resolution at 3 months (RR 1.02, 95% CI 0.95-1.09) or major bleeding (RR 0.54, 95% CI 0.20-1.48) ^[207]^A1a. Warfarin is still commonly used, though DOACs are increasingly considered.

Cancer-Associated VTE. Warfarin is effective but associated with higher bleeding risk than LMWH in cancer patients. The CATCH trial showed tinzaparin reduced clinically relevant bleeding versus warfarin (HR 0.64, 95% CI 0.45-0.89) ^[199]^B2b. DOACs (edoxaban, rivaroxaban) are now preferred in most guidelines, but warfarin remains an option when DOACs are contraindicated.

Positioning Among Anticoagulants

DOACs have largely replaced warfarin for AF and VTE due to fixed dosing, no routine monitoring, and superior safety profiles (lower intracranial hemorrhage, fatal bleeding, and all-cause mortality) ^[120]^A1a^[190]^A1a. However, warfarin remains indispensable for mechanical heart valves, APS (especially triple-positive), and patients with severe renal impairment (creatinine clearance <15 mL/min) where DOACs are not approved. Warfarin's reversibility with vitamin K and fresh frozen plasma is an advantage in settings where antidotes (idarucizumab, andexanet alfa) are unavailable. The choice between warfarin and a DOAC should be individualized based on patient preference, renal function, drug interactions, and cost.

Pearl: Warfarin remains the anticoagulant of choice for mechanical heart valves and high-risk antiphospholipid syndrome; for all other indications, DOACs offer superior safety and convenience, but warfarin's long track record and low cost keep it relevant in resource-limited settings.

Summary of Approved Indications and Key Trial Evidence

Indication	Key Trial(s)	Efficacy vs Comparator	Safety vs Comparator
Atrial Fibrillation	ARISTOTLE, ROCKET AF, RE-LY, ENGAGE AF	DOACs reduce stroke/SE by 19% (RR 0.81) ^[120]^A1a	DOACs reduce ICH by 52% (RR 0.48) ^[120]^A1a
VTE	Hokusai-VTE, AMPLIFY, EINSTEIN	DOACs noninferior to warfarin ^[114]^A1b^[115]^A1b^[116]^A1b	DOACs reduce major bleeding (RR 0.39-0.61) ^[115]^A1b^[116]^A1b
Mechanical Heart Valves	PROACT, RE-ALIGN	Warfarin superior to antiplatelet therapy [label]	Dabigatran increases thromboembolism and bleeding ^[180]^A1b
Post-MI	WARIS, WARIS II	Warfarin reduces mortality and reinfarction [label]	Increased bleeding vs aspirin alone
APS (triple-positive)	TRAPS, RAPS	Warfarin superior to rivaroxaban (HR 6.9) ^[104]^A1b^[197]^A1b	Rivaroxaban increases events

Dose and Administration

▸Warfarin dosing is individualized based on INR response, with target ranges of 2.5 (2.0-3.0) for most indications and 3.0 (2.5-3.5) for mechanical mitral valves.
▸Pharmacogenetic variants in VKORC1 and CYP2C9 explain 30-50% of dose variability; genotype-guided algorithms improve prediction for patients requiring extreme doses.
▸Special populations (pediatric, pregnancy, renal impairment, elderly) require dose adjustments; oral vitamin K effectively reverses asymptomatic over-anticoagulation.

HY High Yield: The VKORC1 AA genotype reduces warfarin dose requirement by ~50% and increases early over-anticoagulation risk; consider a 2.5-3 mg starting dose in these patients.

Once the indication for anticoagulation is established, warfarin dosing must be individualized to achieve the target INR while minimizing bleeding risk. The starting dose, target range, and duration depend on the indication, patient characteristics, and genetic factors.

Initial Dosing

For most patients, warfarin is initiated at 5 mg daily for the first 1-2 days, followed by dose adjustments based on INR response [label]. In Asian populations, a 3 mg starting dose is often used due to lower maintenance requirements; a randomized trial found that 5 mg achieved therapeutic INR earlier by day 5 (53.6% vs 25.0%, p=0.029) but by day 8 the difference was not significant ^[242]^A1b. Lower starting doses (2.5-3 mg) are also appropriate in elderly patients, those with heart failure, hepatic impairment, or known VKORC1 AA genotype ^[229]^B2b. A pharmacogenetics-guided initiation protocol (WRAPID) that incorporates CYP2C9 and VKORC1 genotypes with clinical variables eliminated the influence of genetic variation on time to first therapeutic INR and risk of over-anticoagulation ^[31]^B2b. In postpartum women with pulmonary embolism, a loading dose (first 1-3 days) guided by the International Warfarin Pharmacogenetics Consortium (IWPC) model reduced median time to therapeutic INR from 7 to 5.5 days (p=0.002) without increasing adverse events ^[247]^A1b.

Target INR Ranges

The recommended target INR and duration vary by indication (Table 1). An INR >4 provides no additional therapeutic benefit and increases bleeding risk [label].

Table 1. Target INR Ranges and Durations for Warfarin Therapy

Indication	Target INR (Range)	Duration
Venous thromboembolism (DVT/PE) - provoked by transient risk factor	2.5 (2.0-3.0)	3 months [label]
Venous thromboembolism - unprovoked	2.5 (2.0-3.0)	At least 3 months; reassess risk-benefit for extended therapy [label]
Venous thromboembolism - recurrent (≥2 episodes)	2.5 (2.0-3.0)	Long-term [label]
(non-valvular, high or intermediate risk)	2.5 (2.0-3.0)	Long-term [label]
Atrial fibrillation with	2.5 (2.0-3.0)	Long-term [label]
Mechanical aortic valve (bileaflet or Medtronic Hall, sinus rhythm, normal LA)	2.5 (2.0-3.0)	Long-term [label]
Mechanical mitral valve (tilting disk or bileaflet)	3.0 (2.5-3.5)	Long-term [label]
Caged ball or caged disk valve (any position)	3.0 (2.5-3.5)	Long-term [label]
Bioprosthetic mitral valve	2.5 (2.0-3.0)	First 3 months after implantation [label]

Pharmacogenetics-Guided Dosing

Genetic variants in VKORC1 (especially -1639G>A) and CYP2C9 (*2, *3) explain 30-50% of interindividual variability in warfarin dose ^[43]^B2b^[45]^B2b^[229]^B2b. The VKORC1 AA genotype is associated with a ~50% lower maintenance dose and increased risk of early over-anticoagulation ^[229]^B2b. In African Americans, the rs12777823 variant in CYP2C cluster also influences dose ^[41]^B2b. Pharmacogenetic algorithms improve dose prediction, particularly for patients requiring ≤21 mg/week or ≥49 mg/week ^[49]^B3b. However, early INR response (days 4-6) captures much of the genetic information, and genotype-guided dosing may be most beneficial during the first month of therapy ^[136]^B2b. Race-stratified algorithms outperform race-combined models ^[41]^B2b.

Special Populations

Pediatric: Height, VKORC1 and CYP2C9 genotypes, and indication explain up to 72% of warfarin dose variability in children ^[137]^B2b^[238]^C4. Dosing is extrapolated from adult data; no adequate pediatric trials exist ^[154]^D5.
Pregnancy: Warfarin is contraindicated except in women with mechanical heart valves at high thromboembolic risk. First-trimester exposure causes embryopathy in ~5% of offspring [label]. Effective contraception is required during therapy and for at least 1 month after the last dose [label].
Renal Insufficiency: Creatinine clearance correlates with stable warfarin dose and time to therapeutic INR; patients with moderate renal impairment require lower doses ^[241]^B2b.
Elderly and Frail: Lower starting doses (2.5-3 mg) are recommended. Frailty increases both stroke and bleeding risk; warfarin remains effective but requires careful monitoring ^[237]^B2b.

of Over-Anticoagulation

For asymptomatic patients with INR 4.0-10.0, warfarin should be held and oral vitamin K considered. A tailored vitamin K dose (based on INR and body surface area) returns more patients to target INR within 24 hours than fixed 1 or 2 mg (68.9% vs 52.8%) ^[131]^A1b. Alternatively, a fixed regimen of 2.5 mg for INR 8.0-11.9 and 5 mg for INR ≥12.0 is effective ^[158]^D5. In Chinese patients with mechanical heart valves, oral vitamin K 2.5 mg reduced INR to 1.5-2.5 in 72.5% of patients by the next day vs 0% with placebo, with fewer bleeding events (10% vs 30%) ^[240]^A1b. For serious bleeding, prothrombin complex concentrate is indicated.

Pearl: Initiate warfarin at 5 mg daily for most patients, but reduce to 2.5-3 mg in elderly, Asian, or VKORC1 AA carriers; pharmacogenetics-guided algorithms and early INR monitoring (days 4-6) optimize time in therapeutic range and reduce bleeding risk.

Dose Modification

▸Pharmacogenetic algorithms (CYP2C9, VKORC1) improve dose prediction, especially for patients requiring ≤21 mg/week or ≥49 mg/week.
▸Amiodarone coadministration requires a ~25% warfarin dose reduction with close INR monitoring.
▸For asymptomatic over-anticoagulation (INR >6), tailored vitamin K dosing is more effective than fixed-dose regimens.

HY High Yield: The WRAPID pharmacogenetic protocol eliminates the influence of CYP2C9 and VKORC1 on time to therapeutic INR and over-anticoagulation risk [31].

! Warning: Amiodarone increases INR in >1 in 3 patients within 3 weeks; anticipate a 25% warfarin dose reduction and check INR within 1 week [230].

Genetic variants in CYP2C9 and VKORC1 explain up to 42% of the interindividual variability in warfarin dose requirements, and pharmacogenetic-guided dosing algorithms improve prediction, particularly for patients requiring ≤21 mg/week or ≥49 mg/week ^[43]^B2b^[49]^B3b. The WRAPID protocol, which incorporates CYP2C9 and VKORC1 genotypes along with clinical variables, eliminated the influence of genetic variation on time to first therapeutic INR and risk of over-anticoagulation in a prospective cohort ^[31]^B2b. Race-stratified algorithms outperform race-combined models because the effect of predictors differs by race: CYP2C9*2 lowers dose only in European Americans, while rs12777823 lowers dose only in African Americans ^[41]^B2b. VKORC1 -1639G>A explains greater dose variability in whites than in blacks or Asians, largely due to allele frequency differences ^[45]^B2b. Early INR response (days 4-6) captures much of the genetic information; after week 1 INRs, CYP2C9 and VKORC1 genotypes no longer independently predict stable dose ^[136]^B2b. In children, height, VKORC1 genotype, and CYP2C9 genotype explain 69.7% of warfarin dose variability ^[137]^B2b^[238]^C4.

Renal and Hepatic Impairment

Warfarin is hepatically metabolized; hepatic impairment increases sensitivity to anticoagulation, though no specific dose reduction is mandated, monitor INR more frequently [label]. In patients with compromised renal function, acute kidney injury may occur, especially with excessive anticoagulation and hematuria; closer INR monitoring is advised [label]. Direct oral anticoagulants reduce major bleeding compared with warfarin in stage 4 and stage 5 CKD (OR 0.73 and 0.70, respectively) ^[253]^B2a, but warfarin remains necessary for mechanical heart valves ^[180]^A1b.

Age and Body Weight

Age ≥65 years is an independent risk factor for bleeding [label]. Elderly patients typically require lower maintenance doses. Low body weight is associated with increased thromboembolic risk (RR 1.57) regardless of anticoagulant type, but dose adjustment of warfarin beyond standard monitoring is unlikely to improve outcomes ^[112]^A1a.

Drug Interactions

coadministration increases mean INR from 2.6 to 3.1, with 37% of patients developing INR >3.0; anticipate a 24.6% dose reduction (95% CI 23.5-25.6) and monitor INR within 1 week ^[230]^B3b. Henagliflozin does not significantly alter warfarin PK/PD, so no dose adjustment is needed ^[89]^C4.

of Over-Anticoagulation

For asymptomatic patients with INR >6.0, a tailored vitamin K dose based on index INR and body surface area returns 68.9% to target range within 24 h, compared with 52.8% for fixed 1 mg or 2 mg doses ^[131]^A1b. A practical regimen: 2.5 mg oral vitamin K for INR 8.0-11.9, and 5 mg for INR ≥12.0 ^[158]^D5. Warfarin can be restarted once INR <5.0 ^[158]^D5.

Perioperative Management

For procedures with intermediate or high bleeding risk, warfarin is typically withheld 5 days before surgery; bridging with low-molecular-weight is considered for patients at high thromboembolic risk (e.g., mechanical mitral valve, recent VTE) ^[249]^D5.

Pearl: When starting amiodarone in a warfarin-treated patient, reduce the warfarin dose by approximately 25% and recheck INR within one week to avoid supratherapeutic anticoagulation ^[230]^B3b.

Selected Dose-Modifying Factors for Warfarin

Factor	Effect on Dose	Recommendation
CYP2C9 2/3 carriers	Lower dose required	Use pharmacogenetic algorithm; reduce starting dose by 20-40% ^[43]^B2b^[49]^B3b
VKORC1 -1639A carriers	Lower dose required	Use pharmacogenetic algorithm; reduce starting dose by 30-50% ^[43]^B2b^[45]^B2b
African ancestry (rs12777823)	Lower dose required	Consider race-stratified algorithm ^[41]^B2b
Amiodarone coadministration	Increase INR; need dose reduction	Reduce warfarin dose by ~25% and monitor INR within 1 week ^[230]^B3b
Age ≥65 years	Increased bleeding risk	Lower maintenance dose; more frequent INR monitoring [label]
Hepatic impairment	Increased sensitivity	Monitor INR closely; no fixed dose reduction [label]
Renal impairment (CKD 4-5)	Increased bleeding risk	Monitor INR closely; consider DOAC if appropriate ^[253]^B2a
Low body weight	Higher thromboembolic risk	Standard monitoring; dose adjustment unlikely to improve outcomes ^[112]^A1a

Adverse Effects and Toxicity

▸Bleeding is the most common dose-limiting toxicity; major bleeding occurs at ~3% per year, and intracranial hemorrhage carries a 33% in-hospital mortality.
▸Tissue necrosis, calciphylaxis, and anticoagulation-related nephropathy are rare but serious non-hemorrhagic adverse effects that require prompt recognition and discontinuation of warfarin.
▸Risk factors for hemorrhage include age ≥65, INR >4, hypertension, prior GI bleeding, and renal impairment; maintenance of therapeutic INR does not eliminate bleeding risk.

! Warning: Warfarin can cause major or fatal bleeding. Perform regular INR monitoring and instruct patients to report signs of bleeding (unusual bruising, red or black stools, hematuria, hematemesis) [label].

Dose modification reduces the risk of extreme INR excursions, yet the adverse effects of warfarin remain a function of both intensity and duration of anticoagulation. The most common dose-limiting toxicity is hemorrhage, which can be major or fatal.

Hemorrhage

Warfarin can cause major or fatal bleeding, with the highest risk within the first month of therapy [label]. Risk factors include high-intensity anticoagulation (INR >4), age ≥65 years, highly variable INRs, prior bleeding, , cerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic variants, concomitant drugs, and long treatment duration [label]. Maintenance of a therapeutic INR does not eliminate bleeding risk.

In the ARISTOTLE trial, warfarin-treated patients with experienced major bleeding at a rate of 3.09% per year compared with 2.13% per year for (HR 0.69; 95% CI 0.60-0.80; NNT ≈ 105 per year to prevent one major bleed ^[175]^A1b). Intracranial hemorrhage (ICH) occurred at 0.80% per year with warfarin versus 0.33% per year with apixaban ^[169]^B2b. Among warfarin-treated patients in that trial, the median INR before ICH was 2.6 (IQR 2.1-3.0), and 78.5% had a pre-ICH INR <3.0 ^[169]^B2b. In the RE-LY trial, the rate of ICH with warfarin was 0.38% per year, compared with 0.12% per year for 110 mg and 0.10% per year for dabigatran 150 mg ^[178]^A1b. A meta-analysis of 17 RCTs found that DOACs reduced ICH risk by 54% relative to warfarin (OR 0.46; 95% CI 0.35-0.59) ^[204]^A1a.

In the ROCKET AF trial, major and clinically relevant non-major bleeding occurred at 14.5% per year with warfarin, similar to (14.9% per year; HR 1.03; 95% CI 0.96-1.11) ^[176]^A1b. Fatal bleeding was 0.5% per year with warfarin versus 0.2% per year with rivaroxaban (P=0.003) ^[176]^A1b. A meta-analysis of 8 RCTs comparing warfarin (target INR 2.0-3.5) with showed a trend toward increased major bleeding (OR 1.27) and a significantly higher risk of minor bleeding (OR 1.50; 95% CI 1.13-2.00) ^[189]^A1a.

Major bleeding on warfarin carries substantial short-term mortality. In the ORANGE study, in-hospital mortality after major bleeding was 21% overall and 33% for ICH ^[258]^B2b. The median time from most recent INR to ICH was 13 days in warfarin-treated patients ^[169]^B2b.

Tissue Necrosis and

Warfarin can cause necrosis and/or gangrene of skin and other tissues in <0.1% of patients, typically within a few days of therapy initiation [label]. Necrosis is associated with local thrombosis and may require debridement or amputation. If necrosis occurs, warfarin should be discontinued and alternative anticoagulation considered [label].

Calciphylaxis (calcium uremic arteriolopathy) is a rare but potentially fatal adverse effect reported in patients with and without end-stage renal disease [label]. When diagnosed, warfarin should be stopped and calciphylaxis treated appropriately [label].

Other Adverse Effects

System	Adverse Reactions
Immune	Hypersensitivity/allergic reactions, urticaria,
Vascular	Vasculitis
Hepatobiliary	Hepatitis, elevated liver enzymes; cholestatic hepatitis with concomitant ticlopidine
Gastrointestinal	Nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating
Skin	Rash, dermatitis (including bullous eruptions), pruritus, alopecia
Respiratory	Tracheal or tracheobronchial calcification
General	Chills

[label] also lists systemic atheroemboli and cholesterol microemboli, which can present with a variety of signs depending on the embolization site; the most common visceral organs affected are the kidneys, followed by pancreas, spleen, and liver. A distinct syndrome known as "purple toes syndrome" results from microemboli to the feet [label].

Anticoagulation-Related Nephropathy

Anticoagulation-related nephropathy (ARN) is an underdiagnosed cause of acute kidney injury in patients on warfarin, defined as AKI without obvious etiology in the setting of an INR >3.0 ^[288]^D5. The mechanism is thought to involve glomerular hemorrhage from supratherapeutic anticoagulation. ARN is associated with accelerated progression of chronic kidney disease and increased short- and long-term mortality ^[288]^D5. Prompt recognition is critical; warfarin should be held and the INR corrected.

Bleeding Risk in Special Populations

In patients with chronic liver disease, the relationship between INR and hemorrhage differs from that in warfarin users. As INR rises above 1.5, the adjusted hazard ratio for hemorrhage in CLD patients increased to 2.25 but remained fairly constant with further elevation, whereas in warfarin users the risk increased exponentially with supratherapeutic INR (aHR 4.70 for INR >3.5) ^[257]^B2b. This underscores that an elevated INR in CLD does not predict bleeding risk in the same way as in warfarin therapy.

Pearl: The absolute risk of major bleeding on warfarin is approximately 3% per year, and intracranial hemorrhage accounts for nearly half of major bleeding events; the risk is highest in the first month and with INR >4, but two-thirds of ICH events occur at INR <3.0, emphasizing that therapeutic-range anticoagulation does not eliminate this devastating complication ^[169]^B2b^[175]^A1b.

Drug Interactions

▸Drug interactions with warfarin are a leading cause of preventable harm, mediated by pharmacodynamic (bleeding risk) and pharmacokinetic (CYP450) mechanisms.
▸Paracetamol at 4 g/day potentiates warfarin (mean INR increase 1.20), while carbamazepine reduces effect (dose increase 49%); both require close monitoring.
▸Metformin and other glucose-lowering drugs decrease INR, and cannabinoids may elevate INR; clinicians should routinely assess concomitant use.

! Warning: Paracetamol at doses >2 g/day can significantly potentiate warfarin; this interaction is often underestimated. Monitor INR within one week of starting regular paracetamol.

The adverse effects of warfarin are compounded by its extensive drug interaction profile, making interactions a leading cause of preventable harm. Both pharmacodynamic and pharmacokinetic mechanisms contribute, and the narrow therapeutic index demands vigilance whenever concomitant medications are started, stopped, or dose-changed [label].

Pharmacodynamic Interactions

Pharmacodynamic interactions arise from synergism (impaired hemostasis), competitive antagonism (vitamin K), or altered vitamin K metabolism. Drugs that independently impair hemostasis, antiplatelet agents, NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and other anticoagulants, increase bleeding risk when combined with warfarin ^[301]^D5. The FDA label lists anticoagulants (argatroban, , , etc.) and antiplatelet agents ( , cilostazol, , dipyridamole, , ticlopidine) as drugs that increase bleeding risk [label]. Concomitant use should be routinely assessed and minimized ^[301]^D5.

Pharmacokinetic Interactions

Warfarin is a racemic mixture; the more potent S-enantiomer is metabolized primarily by CYP2C9, while R-warfarin is metabolized by CYP1A2 and CYP3A4 [label]. Inhibitors of these isozymes increase warfarin exposure and INR; inducers decrease effect. Table 2 from the FDA label provides examples [label].

Table 1: Examples of CYP450 Interactions with Warfarin

Enzyme	Inhibitors	Inducers
CYP2C9	, , cotrimoxazole, , fluvastatin, fluvoxamine, , miconazole, sulfinpyrazone,	aprepitant, bosentan, carbamazepine, phenobarbital,
CYP1A2	, cimetidine, fluvoxamine, norfloxacin, ,	cigarette smoking, phenobarbital,
CYP3A4	amiodarone, , , erythromycin, fluconazole, itraconazole, ketoconazole, ritonavir, verapamil	carbamazepine, phenytoin, rifampin,

More frequent INR monitoring is required when starting or stopping any CYP450 inhibitor or inducer [label].

Specific High-Impact Interactions

Paracetamol (acetaminophen): In a double-blind, placebo-controlled crossover study, paracetamol 1 g four times daily for 14 days caused mean INR to rise to a maximum of 3.45 ± 0.78 versus 2.66 ± 0.73 with placebo (p=0.03), with a mean increase from baseline of 1.20 ± 0.62 (p<0.001) ^[191]^A1b. The interaction is dose-dependent and likely mediated by interference with vitamin K-dependent clotting factor synthesis ^[87]^C4. Clinicians should be aware of this clinically significant and underestimated interaction ^[191]^A1b.

Carbamazepine: A register-based cohort study of 166 patients found that carbamazepine initiation increased warfarin dose requirements by 49% and led to subtherapeutic INR in 79% of patients by week 5 ^[231]^B3b. Dose increases exceeding 50% and 100% occurred in 59% and 17% of patients, respectively ^[231]^B3b. Close INR monitoring and anticipatory dose adjustment are essential.

and glucose-lowering drugs: Initiation of metformin in patients on phenprocoumon increased the mean daily dose from 2.13 mg to 2.49 mg within 3 months (mean increase 0.36 mg; 95%) and decreased INR from 2.88 to 2.54 (mean decrease 0.35; 95%) ^[313]^B3b. A self-controlled register study of warfarin and phenprocoumon users found that initiation of any glucose-lowering treatment decreased mean INR from 2.5 to 2.2 (decrease of -0.3; 95% CI -0.1 to -0.5) and led to subtherapeutic INR in more than half of patients ^[314]^B3b. Monitoring should be intensified upon starting antidiabetic therapy.

Cannabinoids: Seven case reports describe elevated INR with cannabis use, with maximum INR changes ranging from +0.4 to +9.61; bleeding occurred in 14.2% of cases ^[308]^B2a. A longitudinal cohort study of older patients found a risk of drug-related intoxication of 2.61 among those exposed to cannabis and narrow-therapeutic-index drugs including warfarin ^[315]^B2b. Clinician awareness is important, though data quality is low ^[308]^B2a.

GLP-1 receptor agonists: These agents delay gastric emptying, reducing Cmax and delaying tmax of warfarin, but overall exposure (AUC) is not clinically significantly altered ^[307]^A1a. Dose adjustment is probably not required, but caution is warranted in patients with kidney dysfunction or when using other narrow-therapeutic-index drugs ^[307]^A1a.

Other notable interactions: Flucloxacillin is a weak inducer of CYP3A4, reducing warfarin efficacy ^[310]^A1b. Henagliflozin, a SGLT-2 inhibitor, showed no clinically relevant PK/PD interaction with warfarin in healthy subjects ^[89]^C4. initiation did not significantly alter the warfarin dose/INR ratio in a retrospective study of 102 patients ^[311]^B3b.

These interactions are particularly hazardous in older adults and those with polypharmacy, as discussed in the next section.

Pearl: When starting or stopping any interacting drug, especially paracetamol at doses >2 g/day, carbamazepine, metformin, or cannabis, check INR within 3-5 days and adjust warfarin dose proactively; the interaction with paracetamol is dose-dependent and often overlooked.

Special Populations and Contraindications

▸Warfarin is contraindicated in pregnancy except for mechanical heart valves; doses <5 mg daily reduce fetal complications.
▸Age and body surface area are the strongest predictors of warfarin dose in children, outweighing genetic factors.
▸Lupus anticoagulant in APS can falsely elevate INR, requiring alternative monitoring strategies.

! Warning: Warfarin embryopathy occurs in ~5% of exposed pregnancies; verify pregnancy status before initiating and counsel on effective contraception [label].

HY High Yield: In children with Kawasaki disease and coronary aneurysms, warfarin plus aspirin reduces MI and mortality compared to aspirin alone [325].

Drug interactions are not the only challenge; several patient populations require distinct dosing and monitoring strategies due to altered pharmacokinetics, developmental hemostasis, or pregnancy-related risks.

Contraindications

Warfarin is absolutely contraindicated in pregnancy (except mechanical heart valves), hemorrhagic tendencies, recent CNS/eye surgery, active bleeding (GI, GU, respiratory), CNS hemorrhage, cerebral aneurysms, dissecting aorta, pericarditis, bacterial endocarditis, threatened abortion, eclampsia, preeclampsia, malignant , and hypersensitivity to warfarin [label]. It is also contraindicated in unsupervised patients with high non-compliance risk and during spinal puncture or major regional anesthesia [label].

Pregnancy

Warfarin crosses the placenta and causes a pattern of congenital malformations in about 5% of exposed offspring, including nasal hypoplasia, stippled epiphyses (chondrodysplasia punctata), and CNS abnormalities [label]. The drug is contraindicated in pregnancy except in women with mechanical heart valves at high thromboembolic risk [label]. For most indications, low-molecular-weight (LMWH) or unfractionated heparin is preferred during the first trimester and near term. A meta-analysis of 24 studies found that warfarin doses <5 mg daily were associated with lower fetal complications, while LMWH/UFH carried higher maternal thromboembolic events but fewer fetal complications ^[324]^A1a. Delivery planning requires transitioning to heparin before scheduled delivery to allow . Warfarin is not detected in breast milk in a limited study of 15 nursing mothers, but infants should be monitored for bruising or bleeding [label].

Pediatrics

Adequate pediatric trials are lacking; dosing is extrapolated from adults ^[316]^D5. Age is the strongest determinant of warfarin dose, explaining 28.3% of variability, while VKORC1 and CYP2C9 genotypes contribute only 3.7% and 0.4%, respectively ^[320]^B2b. Height and body surface area are also major predictors ^[137]^B2b^[98]^B2b. Pharmacogenetic algorithms derived from adults overestimate pediatric doses, so pediatric-specific algorithms are needed ^[238]^C4^[52]^C4. Indications include with coronary artery aneurysms: adding warfarin to reduced myocardial infarction (OR 0.26) and mortality (OR 0.18) ^[325]^A1a. In cerebral sinus venous thrombosis, children have higher recanalization rates (87% vs 67.5%) and shorter treatment duration than adults ^[328]^B2b. LMWH is often preferred over warfarin in young children due to easier monitoring and fewer dietary interactions ^[316]^D5^[321]^D5.

Elderly

Elderly patients have increased sensitivity to warfarin due to lower body weight, declining renal function, polypharmacy, and comorbidities. Lower starting doses (2-3 mg) and more frequent INR monitoring are recommended. The risk of major bleeding rises with age, particularly in those with a history of falls or frailty. No specific dose adjustment is mandated by the label, but clinical vigilance is essential [label].

Immunocompromised and Comorbidities

In antiphospholipid syndrome (APS), lupus anticoagulant can interfere with INR measurement, potentially overestimating anticoagulation intensity ^[331]^D5. Life-long warfarin is standard, but direct oral anticoagulants are not recommended due to increased thrombotic risk ^[319]^D5. Hereditary antithrombin deficiency often requires higher warfarin doses or adjunctive antithrombin concentrate; in the ATHN registry, 32% of patients used warfarin and 35% received antithrombin concentrate without adverse events ^[327]^B2b. Renal impairment does not require dose adjustment but increases bleeding risk; hepatic impairment amplifies INR response due to reduced synthesis of clotting factors.

Pearl: In pregnant women with mechanical heart valves, warfarin <5 mg daily minimizes fetal risk while maintaining maternal thromboembolic protection; in children, age and height are more important than genetics for dose prediction.

Monitoring and Follow-up

▸INR monitoring is the cornerstone of warfarin management; frequency depends on stability, with intervals extending to 6-8 weeks in patients with consistently stable INRs.
▸Time in therapeutic range (TTR) above 65% is associated with lower rates of thromboembolism and bleeding; TTR below 60% should prompt investigation into adherence, drug interactions, or dietary vitamin K intake.
▸Patient self-testing and pharmacist-led models improve TTR and reduce adverse events, but routine pharmacogenomic-guided dosing has mixed evidence and diminishing utility after the first week of therapy.

HY High Yield: A TTR below 60% should prompt investigation into adherence, drug interactions, or dietary vitamin K intake.

! Warning: Warfarin is the leading cause of emergency hospitalizations for adverse drug events in older adults, accounting for 33.3% of such admissions [337].

Building on the considerations for special populations, the monitoring framework for warfarin must be equally rigorous to maintain efficacy and safety. The cornerstone of warfarin is the (INR), a standardized measure of the prothrombin time that reflects the anticoagulant effect of vitamin K antagonism ^[9]^D5. Unlike direct oral anticoagulants, warfarin requires regular laboratory monitoring due to its narrow therapeutic index and variable pharmacokinetics ^[88]^D5. The goal is to maintain the INR within the target range, typically 2.0 to 3.0 for most indications, or 2.5 to 3.5 for mechanical heart valves, while minimizing time outside this window ^[9]^D5.

Baseline Assessment

Before initiating warfarin, obtain a , liver function tests, and baseline INR. Document the patient's age, weight, concomitant medications (especially , , and ), and dietary vitamin K intake ^[303]^D5. Genotyping for and polymorphisms can identify patients at risk for extreme sensitivity or resistance, though its routine use remains debated ^[38]^D5. The VKORC1 AA genotype is associated with a significantly shortened time to therapeutic INR, a reduced stable warfarin dose, and an increased number of INRs >5 during the first month of therapy ^[229]^B2b. However, after the first week of treatment, INR response and prior dose become increasingly predictive of therapeutic dose, and genotype becomes less relevant, accounting for only 12% of dose variability at day 7 and 1% at day 21 ^[335]^B2b.

INR Monitoring Frequency and Targets

INR monitoring is most frequent during initiation, daily or every other day until the INR is in the therapeutic range for at least two consecutive measurements ^[303]^D5. Once stable, the interval can be extended to weekly, then every 2 to 4 weeks. For patients with consistently stable INRs (all values within the target range over several months), intervals may be extended beyond 4 weeks. A retrospective cohort study found that patients with stable INR control were significantly less likely to have a target INR of 3.0 or higher or chronic diseases such as heart failure and diabetes ^[336]^B2b. The FCSA position paper recommends that after 3 months of stable control, monitoring every 6 to 8 weeks is acceptable ^[303]^D5.

INR Value	Clinical Action
<1.5 (subtherapeutic)	Increase dose by 10-20%; recheck in 3-7 days
1.5-1.9 (below range)	Increase dose by 5-15%; recheck in 1-2 weeks
2.0-3.0 (therapeutic)	Continue current dose; recheck per schedule
3.1-4.0 (supratherapeutic, asymptomatic)	Hold 1-2 doses; reduce dose by 10-20%; recheck in 1-2 weeks
4.0-5.0 (supratherapeutic, no bleeding)	Hold 1-2 doses; consider low-dose vitamin K (1-2.5 mg oral); recheck in 24-48 hours
>5.0 (supratherapeutic, no bleeding)	Hold warfarin; give vitamin K 2.5-5 mg oral; recheck INR in 24 hours
>5.0 with major bleeding	Hold warfarin; give vitamin K 10 mg IV; consider PCC or FFP; recheck INR immediately

Time in Therapeutic Range (TTR)

TTR is the most important quality metric for warfarin management. A TTR above 65% is associated with lower rates of thromboembolism and bleeding ^[336]^B2b. In the RE-COVER trial, the mean TTR for warfarin-treated patients was approximately 60% ^[332]^A1b. A TTR below 60% should prompt investigation into adherence, drug interactions, or dietary vitamin K intake. The pharmacist-led genotype-guided dosing strategy improved TTR during the first two and three follow-up months compared to traditional dosing (57.2% vs 56.2% at 2 months; 62.9% vs 61.7% at 3 months) ^[341]^B2b. Bayesian dose individualization using a web-based calculator (NextDose) also increased median TIR (time in acceptable range) from 71% to 74% over the entire follow-up period and reduced the hazard of clinically relevant minor bleeding (HR 0.21, P=0.041) ^[235]^A1b.

Self-Testing and Pharmacist-Led Models

Patient self-testing (PST) with a point-of-care INR device allows more frequent monitoring and greater patient involvement. In a multicenter randomized trial in China, a pharmacist-led PST model achieved a significantly higher TTR (67.2% vs 55.1%) and lower incidences of major bleeding (0.7% vs 7.9%) and thromboembolism (0.4% vs 6.8%) compared to usual care ^[208]^A1b. However, the THINRS trial found that weekly self-testing did not significantly delay the time to first stroke, major bleeding episode, or death compared to monthly high-quality clinic testing (HR 0.88, 95% CI 0.75-1.04, P=0.14) ^[333]^A1b. Self-testing did improve patient satisfaction and quality of life ^[333]^A1b. The FCSA recommends PST only for motivated patients who have demonstrated stable INR control and have received adequate training ^[303]^D5.

Pharmacogenomic-Guided Dosing

Despite initial promise, the evidence for routine pharmacogenomic-guided dosing remains mixed. The COAG trial showed no benefit of adding genetic information to clinical information on anticoagulation control ^[38]^D5. In contrast, the EU-PACT UK trial found that a pharmacogenetic algorithm improved the primary outcome compared to fixed dosing ^[38]^D5. A pharmacist-led genotype-guided dosing strategy in valve replacement patients improved TTR and shortened the time to stable maintenance dose ^[341]^B2b. Given the diminishing predictive value of genotype after the first week of therapy, the most practical approach is to use a clinical algorithm that incorporates INR response and prior dose, with genotype reserved for patients with unexplained extreme sensitivity or resistance ^[335]^B2b.

Alternative Monitoring: Fiix-Prothrombin Time

The Fiix-prothrombin time (Fiix-PT) measures only factors II and X, ignoring factor VII, which has little effect on thrombin generation ^[334]^B2b. During warfarin induction, Fiix-PT monitoring stabilizes anticoagulation earlier than traditional PT-INR monitoring ^[334]^B2b. In a real-world interrupted time series study, replacing PT-INR monitoring with Fiix-NR monitoring was associated with a 56% reduction in thromboembolism (from 2.82% to 1.23% per patient-year) without an increase in major bleeding ^[265]^B2b. Fiix monitoring also reduced testing frequency, dose adjustments, and normalized ratio variability ^[265]^B2b. This approach is not yet widely adopted but represents a promising alternative for improving warfarin management.

Long-Term Follow-Up and Adherence

Adherence to warfarin is critical but often suboptimal. In a large US commercial insurance database, 72% of warfarin users were nonpersistent at 12 months, defined as a ≥30-day treatment gap or switching ^[339]^B2b. Warfarin users had higher measured adherence than DOAC users in a Taiwanese cohort of older valve surgery patients, but DOAC users had lower observed 1-year mortality (4.31% vs 8.36%) ^[23]^B2b. A history of ischemic stroke or TIA is associated with mixed effects on subsequent adherence; some studies show increased adherence after a first stroke, while others show decreased adherence with recurrent events ^[25]^D5. Warfarin is the leading cause of emergency hospitalizations for adverse drug events in older adults, accounting for 33.3% of such admissions ^[337]^B2c. Therefore, every follow-up visit should include a structured assessment of adherence, drug interactions (especially with and ), dietary changes, and bleeding or thrombotic events ^[230]^B3b^[87]^C4.

Special Monitoring Situations

Antiphospholipid Syndrome (APS): In patients with APS, the INR may not accurately reflect anticoagulation intensity due to interference of lupus anticoagulant with thromboplastin reagents ^[331]^D5. Alternative monitoring strategies include using a chromogenic factor Xa assay or a specific PT reagent less sensitive to lupus anticoagulant ^[331]^D5. Warfarin remains the mainstay for thrombotic APS, but careful monitoring is essential.

: Cancer patients on warfarin have a high risk of clinically relevant bleeding (15.3% over 6 months), particularly those aged >75 years or with intracranial malignancy ^[199]^B2b. Warfarin was associated with improved overall survival compared to LMWH in a population-based study (median OS 9.8 vs 7.2 months, HR 0.86, 95% CI 0.83-0.90) ^[340]^B2b. However, the risk of ischemic stroke after cancer-associated VTE is 5.2% at 6 months with warfarin, and , , and prior stroke are significant risk factors ^[272]^B2b.

Perioperative Management: For elective procedures, warfarin is typically stopped 5 days before surgery to allow the INR to normalize. Bridging with LMWH is reserved for patients at high thromboembolic risk (e.g., mechanical mitral valve, recent VTE). Postoperatively, warfarin is restarted at the usual maintenance dose once hemostasis is assured, and the INR is checked daily until therapeutic.

Pediatric Patients: Warfarin monitoring in children is challenging due to age-related changes in the hemostatic system and limited evidence from prospective studies ^[154]^D5. Frequent INR monitoring is required, and the target range is the same as for adults. Central venous is common in children, but thromboprophylaxis with warfarin has not been shown to reduce the risk (RR 0.85) ^[129]^B2a.

Pearl: The single most actionable metric in warfarin management is the time in therapeutic range (TTR); a TTR below 60% identifies patients at highest risk for both thromboembolism and bleeding, warranting intensified monitoring or a switch to a direct oral anticoagulant if appropriate.

References

[1]
Raskob GE, van Es N, Segers A et al.. “Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.” The Lancet. Haematology (2016). PMID: 27476789 ↗
L1RCTCited in: Introduction and Chemical Structure, Pharmacodynamics, Indications and Clinical Use
[2]
Prins MH, Lensing AW, Brighton TA et al.. “Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.” The Lancet. Haematology (2014). PMID: 27030066 ↗
L1RCTCited in: Introduction and Chemical Structure, Pharmacodynamics
[3]
Palumbo A, Rajkumar SV, Dimopoulos MA et al.. “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.” Leukemia (2007). PMID: 18094721 ↗
L5GUIDELINECited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
[4]
Hijazi Z, Oldgren J, Lindbäck J et al.. “The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.” Lancet (London, England) (2016). PMID: 27056738 ↗
L2RCTCited in: Introduction and Chemical Structure, Indications and Clinical Use
[5]
Agnelli G, Buller HR, Cohen A et al.. “Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26407753 ↗
L1RCTCited in: Introduction and Chemical Structure
[6]
Ditkofsky N, Hanna T. “Images in Clinical Medicine. Spontaneous Retropharyngeal Hematoma.” The New England journal of medicine (2016). PMID: 26789902 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[7]
Wardrop D, Keeling D. “The story of the discovery of heparin and warfarin.” British journal of haematology (2008). PMID: 18355382 ↗
L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure
[8]
Oldenburg J, Watzka M, Rost S et al.. “VKORC1: molecular target of coumarins.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17635701 ↗
L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure
[9]
Raza S, Pinkerton P, Hirsh J et al.. “The historical origins of modern international normalized ratio targets.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38795872 ↗
L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure, Monitoring and Follow-up
[10]
Gurnari C, Awada H, Pagliuca S et al.. “Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis.” Blood (2024). PMID: 38513233 ↗
L2OTHERCited in: Introduction and Chemical Structure, Pharmacodynamics
[11]
Haque JA, McDonald MG, Kulman JD et al.. “A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.” Blood (2013). PMID: 24297869 ↗
L5OTHERCited in: Introduction and Chemical Structure
[12]
Czogalla KJ, Liphardt K, Höning K et al.. “VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.” Blood advances (2018). PMID: 29581108 ↗
L5OTHERCited in: Introduction and Chemical Structure, Pharmacodynamics, Dose and Administration, Dose Modification
[13]
Ashley EA, Butte AJ, Wheeler MT et al.. “Clinical assessment incorporating a personal genome.” Lancet (London, England) (2010). PMID: 20435227 ↗
L4OTHERCited in: Introduction and Chemical Structure, Mechanism of Action, Resistance and Pharmacogenomics
[14]
Hijazi Z, Lindbäck J, Oldgren J et al.. “Evaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarin.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41644239 ↗
L2OTHERCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
[15]
Virk ZM, Zhang E, Rodriguez-Lopez J et al.. “Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36695393 ↗
L2OTHERCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
[16]
de Winter MA, Uijl A, Büller HR et al.. “Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36696208 ↗
L2OTHERCited in: Introduction and Chemical Structure
[17]
Shen G, Li S, Cui W et al.. “Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29665197 ↗
L5OTHERCited in: Introduction and Chemical Structure, Resistance and Pharmacogenomics
[18]
Gallagher AM, Rietbrock S, Plumb J et al.. “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18573187 ↗
L2OTHERCited in: Introduction and Chemical Structure
[19]
Sayar Z, Speed V, Patel JP et al.. “The perils of inhibiting deficient factors.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29883037 ↗
L4OTHERCited in: Introduction and Chemical Structure
[20]
Vlazny DT, Pasha AK, Kuczmik W et al.. “Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34060224 ↗
L2OTHERCited in: Introduction and Chemical Structure
[21]
Muzny CA, Lillis RA, Chavoustie SE et al.. “Refining Trichomonas vaginalis treatment in women and men: protocol for an open-label randomised comparison of multi-dose oral metronidazole versus single-dose oral secnidazole.” BMJ open (2026). PMID: 42031495 ↗
L5TRIAL_NONRANDOMCited in: Introduction and Chemical Structure, Pharmacokinetics (LADME)
[22]
Yang W, Park HK, Koh SH et al.. “Comparison of clopidogrel-based antiplatelet therapy versus warfarin as a secondary prevention strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE): Rationale and design of a prospective, randomized, open-label, blinded-endpoint trial.” Contemporary clinical trials (2025). PMID: 41308951 ↗
L5TRIAL_NONRANDOMCited in: Introduction and Chemical Structure
[23]
Roan JN, Hu YS, Chuang TJ et al.. “Anticoagulant adherence and associated complications and readmissions in older valve surgery adults: insights from a retrospective cohort study.” BMC geriatrics (2026). PMID: 41957737 ↗
L2COHORTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity, Monitoring and Follow-up
[24]
Abdin B, Abuqweider E, Alhaddad I et al.. “The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study - A Prospective Cohort Study.” BMJ open (2025). PMID: 41461398 ↗
L2COHORTCited in: Introduction and Chemical Structure
[25]
Shukkoor AA, Turgeon RD, De Vera MA et al.. “Association of ischaemic stroke/TIA with subsequent oral anticoagulant adherence in patients with atrial fibrillation: a scoping review.” BMJ open (2026). PMID: 42331577 ↗
L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure, Monitoring and Follow-up
[26]
Alasmar R, Ibrahim R, AlHammouri H et al.. “Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 41838376 ↗
L3COHORTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
[27]
Nagai K, Mitani T, Kawahara Y et al.. “A pediatric case of anti-PF4 antibody-induced cerebral venous sinus thrombosis and thrombocytopenia following adenovirus infection: a literature review.” Brain & development (2025). PMID: 41213226 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[28]
Yaman R, Arango Martinez A, Padula CA et al.. “Segmental Arterial Mediolysis and Other Mimics of Medium Vessel Vasculitis: A Case and Review.” Journal of clinical medicine (2026). PMID: 42194812 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[29]
Zhang X, Liu X, Duan L et al.. “Pregnancy with treacher collins syndrome in mechanical heart valve: a case report and discussion treacher collins syndrome and MHV.” BMC pregnancy and childbirth (2026). PMID: 42032534 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[30]
Mitchell S, Rojas OG, Mathavan A et al.. “A 36-Year-Old Man With Hemoptysis and Fevers.” Chest (2026). PMID: 41672657 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[31]
Gong IY, Tirona RG, Schwarz UI et al.. “Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.” Blood (2011). PMID: 21725053 ↗
L2RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
[32]
Kimmel SE, French B, Kasner SE et al.. “A pharmacogenetic versus a clinical algorithm for warfarin dosing.” The New England journal of medicine (2013). PMID: 24251361 ↗
L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics
[33]
Pirmohamed M, Burnside G, Eriksson N et al.. “A randomized trial of genotype-guided dosing of warfarin.” The New England journal of medicine (2013). PMID: 24251363 ↗
L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics, Indications and Clinical Use
[34]
Pérez-Andreu V, Roldán V, Antón AI et al.. “Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.” Blood (2009). PMID: 19270263 ↗
L2TRIAL_NONRANDOMCited in: Mechanism of Action, Resistance and Pharmacogenomics
[35]
Wang D, Chen H, Momary KM et al.. “Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.” Blood (2008). PMID: 18523153 ↗
L5TRIAL_NONRANDOMCited in: Mechanism of Action, Resistance and Pharmacogenomics
[36]
Mega JL, Walker JR, Ruff CT et al.. “Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.” Lancet (London, England) (2015). PMID: 25769357 ↗
L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics, Indications and Clinical Use, Adverse Effects and Toxicity
[37]
Franchini M, Mengoli C, Cruciani M et al.. “Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 25040440 ↗
L1SR_OBSCited in: Mechanism of Action, Resistance and Pharmacogenomics, Indications and Clinical Use
[38]
Kimmel SE. “Warfarin pharmacogenomics: current best evidence.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149035 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics, Adverse Effects and Toxicity, Monitoring and Follow-up
[39]
Ross S, Nejat S, Paré G. “Use of genetic data to guide therapy in arterial disease.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149037 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacokinetics (LADME), Pharmacodynamics
[40]
Price ET. “Warfarin pharmacogenomics and African ancestry.” Blood (2015). PMID: 26206946 ↗
L5OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
[41]
Limdi NA, Brown TM, Yan Q et al.. “Race influences warfarin dose changes associated with genetic factors.” Blood (2015). PMID: 26024874 ↗
L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
[42]
Tie JK, Jin DY, Straight DL et al.. “Functional study of the vitamin K cycle in mammalian cells.” Blood (2011). PMID: 21239697 ↗
L5OTHERCited in: Mechanism of Action
[43]
Wadelius M, Chen LY, Lindh JD et al.. “The largest prospective warfarin-treated cohort supports genetic forecasting.” Blood (2008). PMID: 18574025 ↗
L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
[44]
Parker AL, Waddington SN, Nicol CG et al.. “Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.” Blood (2006). PMID: 16788098 ↗
L5OTHERCited in: Mechanism of Action
[45]
Limdi NA, Wadelius M, Cavallari L et al.. “Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.” Blood (2010). PMID: 20203262 ↗
L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Dose and Administration, Dose Modification
[46]
Daneshjou R, Gamazon ER, Burkley B et al.. “Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.” Blood (2014). PMID: 25079360 ↗
L3OTHERCited in: Mechanism of Action
[47]
Park IK, Giovenzana C, Hughes TL et al.. “The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.” Blood (2008). PMID: 18840707 ↗
L5OTHERCited in: Mechanism of Action
[48]
Cooper GM, Johnson JA, Langaee TY et al.. “A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.” Blood (2008). PMID: 18535201 ↗
L3OTHERCited in: Mechanism of Action
[49]
Klein TE, Altman RB, Eriksson N et al.. “Estimation of the warfarin dose with clinical and pharmacogenetic data.” The New England journal of medicine (2009). PMID: 19228618 ↗
L3OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification, Special Populations and Contraindications
[50]
Morris SA, Alsaidi AT, Verbyla A et al.. “Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.” Clinical pharmacology and therapeutics (2022). PMID: 36149409 ↗
L1SR_OBSCited in: Mechanism of Action, Resistance and Pharmacogenomics
[51]
Bortman LV, Mitchell F, Naveiro S et al.. “Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation.” Journal of clinical pharmacology (2023). PMID: 36433678 ↗
L5SR_OBSCited in: Mechanism of Action
[52]
Vear SI, Ayers GD, Van Driest SL et al.. “The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.” British journal of haematology (2014). PMID: 24601977 ↗
L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Special Populations and Contraindications
[53]
Ndadza A, Muyambo S, Mntla P et al.. “Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34382722 ↗
L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
[54]
Lenzini PA, Grice GR, Milligan PE et al.. “Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18662264 ↗
L2OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
[55]
Hernandez W, Gamazon ER, Aquino-Michaels K et al.. “Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28135054 ↗
L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics
[56]
Lubitz SA, Scott SA, Rothlauf EB et al.. “Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20128861 ↗
L4OTHERCited in: Mechanism of Action, Resistance and Pharmacogenomics, Dose and Administration, Dose Modification
[57]
Rieder MJ, Reiner AP, Rettie AE. “Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17764537 ↗
L4OTHERCited in: Mechanism of Action
[58]
Abohelaika S, Wynne H, Avery P et al.. “Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26010205 ↗
L2OTHERCited in: Mechanism of Action
[59]
Waizenegger JS, Ben-Batalla I, Weinhold N et al.. “Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.” Leukemia (2014). PMID: 25102945 ↗
L5OTHERCited in: Mechanism of Action
[60]
Anand A, Hegde NC, Chhabra P et al.. “Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.” Annals of hematology (2024). PMID: 38634917 ↗
L1RCTCited in: Mechanism of Action, Resistance and Pharmacogenomics
[61]
Jannati S, Patnaik R, Banerjee Y. “Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling.” International journal of molecular sciences (2024). PMID: 39201414 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action
[62]
Zubiaur P, Rodríguez-Antona C, Boone EC et al.. “PharmVar GeneFocus: CYP4F2.” Clinical pharmacology and therapeutics (2024). PMID: 39135485 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics
[63]
Ingelman-Sundberg M, Pirmohamed M. “Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.” Journal of internal medicine (2024). PMID: 38343077 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics
[64]
Ross S, Krebs K, Paré G et al.. “Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art.” Stroke (2022). PMID: 36325912 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action, Resistance and Pharmacogenomics
[65]
Thompson LE, Davis BH, Narayan R et al.. “Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics.” Clinical pharmacology and therapeutics (2022). PMID: 35857814 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action
[66]
Svyatova G, Berezina G, Murtazaliyeva A et al.. “GENETIC ASPECTS OF WARFARIN DOSING ALGORITHMS IN CARDIAC SURGERY PATIENTS WHO HAVE UNDERGONE HEART SURGERY: SYSTEMATIC REVIEW.” Georgian medical news (2025). PMID: 40884373 ↗
L2SR_OBSCited in: Mechanism of Action
[67]
Ranasinghe P, Jeyapragasam H, Liyanage S et al.. “Pharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications.” Pharmacogenomics (2024). PMID: 39540556 ↗
L2SR_OBSCited in: Mechanism of Action
[68]
Shi K, Deng J. “Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.” Pharmacogenetics and genomics (2024). PMID: 39356590 ↗
L5TRIAL_NONRANDOMCited in: Mechanism of Action, Resistance and Pharmacogenomics, Dose Modification
[69]
Wong HJ, Teo YN, Teo YH et al.. “Subgroup analysis of genotype guided vs traditional warfarin dosing in Asian patients from an open label randomized trial.” Scientific reports (2026). PMID: 41484425 ↗
L1RCTCited in: Mechanism of Action
[70]
Shamohammadi M, Nazari MA, Mirkalaie SMM et al.. “Artificial intelligence and machine learning for precision warfarin dosing: a comprehensive narrative review.” European journal of clinical pharmacology (2026). PMID: 41649565 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action
[71]
Spahn C, Walker T, Byurat S et al.. “The Use of Pharmacogenomics in Cardiovascular Care.” The Nursing clinics of North America (2025). PMID: 40345762 ↗
L5REVIEW_NARRATIVECited in: Mechanism of Action
[72]
Cohen H, Sayar Z, Efthymiou M et al.. “Management of anticoagulant-refractory thrombotic antiphospholipid syndrome.” The Lancet. Haematology (2020). PMID: 32735839 ↗
L5REVIEW_NARRATIVECited in: Resistance and Pharmacogenomics
[73]
Czogalla KJ, Biswas A, Wendeln AC et al.. “Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.” Blood (2013). PMID: 23982176 ↗
L5OTHERCited in: Resistance and Pharmacogenomics
[74]
Chen X, Jin DY, Stafford DW et al.. “Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu.” Blood (2018). PMID: 30089628 ↗
L5OTHERCited in: Resistance and Pharmacogenomics, Pharmacodynamics
[75]
Loebstein R, Dvoskin I, Halkin H et al.. “A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.” Blood (2006). PMID: 17110455 ↗
L3OTHERCited in: Resistance and Pharmacogenomics, Pharmacodynamics, Dose and Administration, Dose Modification
[76]
Harrington DJ, Gorska R, Wheeler R et al.. “Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18680536 ↗
L4OTHERCited in: Resistance and Pharmacogenomics, Pharmacokinetics (LADME)
[77]
Tie JK, Jin DY, Tie K et al.. “Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23710884 ↗
L5OTHERCited in: Resistance and Pharmacogenomics
[78]
Sabry S, El Wakeel LM, Saleh A et al.. “Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.” Clinical drug investigation (2022). PMID: 35274222 ↗
L1RCTCited in: Resistance and Pharmacogenomics
[79]
Marathe SP, Van Dyk S, Campbell S et al.. “Platelet responsiveness to aspirin in pediatric patients undergoing cardiac surgery: A prospective cohort study.” The Journal of thoracic and cardiovascular surgery (2025). PMID: 40975432 ↗
L2COHORTCited in: Resistance and Pharmacogenomics, Dose Modification, Special Populations and Contraindications
[80]
Lee KJ, Kang M, Lee EJ et al.. “Clinical Application of Pharmacogenomics in Stroke Management: Current Evidence and Future Directions.” Journal of stroke (2026). PMID: 41656635 ↗
L5REVIEW_NARRATIVECited in: Resistance and Pharmacogenomics
[81]
Salem M, El-Bardissy A, Elshafei MN et al.. “Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case-Control Study.” Clinical pharmacology and therapeutics (2023). PMID: 36789833 ↗
L3CASE_CONTROLCited in: Resistance and Pharmacogenomics
[82]
Kim B, Song J, Kang J et al.. “A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41651288 ↗
L4RCTCited in: Pharmacokinetics (LADME), Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[83]
Spyropoulos AC, Douketis JD. “How I treat anticoagulated patients undergoing an elective procedure or surgery.” Blood (2012). PMID: 22932800 ↗
L5CASE_REPORTCited in: Pharmacokinetics (LADME)
[84]
Nakamura M, Wang YQ, Wang C et al.. “Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26179767 ↗
L2RCTCited in: Pharmacokinetics (LADME), Pharmacodynamics
[85]
Schulman S, Crowther MA. “How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.” Blood (2012). PMID: 22302737 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME), Drug Interactions
[86]
Schulman S, Furie B. “How I treat poisoning with vitamin K antagonists.” Blood (2014). PMID: 25377783 ↗
L5CASE_REPORTCited in: Pharmacokinetics (LADME), Adverse Effects and Toxicity
[87]
Lopes RD, Horowitz JD, Garcia DA et al.. “Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility.” Blood (2011). PMID: 21911832 ↗
L4CASE_REPORTCited in: Pharmacokinetics (LADME), Adverse Effects and Toxicity, Drug Interactions, Monitoring and Follow-up
[88]
Bauer KA. “Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21781237 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME), Monitoring and Follow-up
[89]
He X, Liu G, Chen X et al.. “Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.” Clinical therapeutics (2023). PMID: 37451912 ↗
L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME), Dose Modification, Drug Interactions
[90]
Pooler DB, Ness DB, Sarantopoulos J et al.. “The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.” British journal of clinical pharmacology (2020). PMID: 32736411 ↗
L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
[91]
Zhu Y, Xu Y, Zhuang Y et al.. “Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.” Clinical and translational science (2020). PMID: 32407591 ↗
L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
[92]
Pinquier JL, Varastet M, Meyers D et al.. “A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.” Clinical pharmacology in drug development (2021). PMID: 33434399 ↗
L1RCTCited in: Pharmacokinetics (LADME)
[93]
Alodat L, Shahin W, Breik L et al.. “Stability of Medications Administered via Enteral Feeding Tubes: A Systematic Review.” Clinical and translational science (2026). PMID: 41443608 ↗
L5SR_OBSCited in: Pharmacokinetics (LADME)
[94]
Khalid A, Khalid A, Waite S et al.. “Exploring the use of electroconvulsive therapy in the anticoagulated population: A systematic review.” The Australian and New Zealand journal of psychiatry (2024). PMID: 39252452 ↗
L2SR_OBSCited in: Pharmacokinetics (LADME)
[95]
Ishiguchi H, Chen Y, Huang B et al.. “Machine learning for stroke in heart failure with reduced ejection fraction but without atrial fibrillation: A post-hoc analysis of the WARCEF trial.” European journal of clinical investigation (2024). PMID: 39552607 ↗
L2RCTCited in: Pharmacokinetics (LADME)
[96]
Desch M, Schlecker C, Hohl K et al.. “Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.” Journal of clinical psychopharmacology (2023). PMID: 36700734 ↗
L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME), Drug Interactions
[97]
Ramírez J, House LK, Karrison TG et al.. “Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.” Journal of clinical pharmacology (2019). PMID: 31274208 ↗
L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
[98]
Maagdenberg H, Bierings MB, van Ommen CH et al.. “The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29935043 ↗
L2OTHERCited in: Pharmacokinetics (LADME), Dose and Administration, Dose Modification, Special Populations and Contraindications
[99]
Rupin A, Marx I, Vallez MO et al.. “S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21481181 ↗
L5OTHERCited in: Pharmacokinetics (LADME)
[100]
Hu C, Chen X, Zhao Z et al.. “A Two-Sequence, Four-Period, Crossover, Replicate Study to Demonstrate Bioequivalence of Warfarin Sodium Tablet in Healthy Chinese Subjects Under Fasting and Fed Conditions.” Clinical pharmacology in drug development (2020). PMID: 32052925 ↗
L1RCTCited in: Pharmacokinetics (LADME)
[101]
Gomes Freitas C, Walsh M, Coutinho EL et al.. “Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial.” PloS one (2021). PMID: 33793580 ↗
L1RCTCited in: Pharmacokinetics (LADME)
[102]
Rodríguez-Bernal CL, Santa-Ana-Téllez Y, García-Sempere A et al.. “Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study.” British journal of clinical pharmacology (2020). PMID: 32530052 ↗
L2COHORTCited in: Pharmacokinetics (LADME)
[103]
Sathe AG, Othman AA, Mohamed MF. “Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.” Journal of clinical pharmacology (2020). PMID: 32960975 ↗
L4SR_OBSCited in: Pharmacokinetics (LADME)
[104]
Pengo V, Denas G, Zoppellaro G et al.. “Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.” Blood (2018). PMID: 30002145 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[105]
Raskob G, Ageno W, Cohen AT et al.. “Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.” The Lancet. Haematology (2016). PMID: 27132697 ↗
L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[106]
Palumbo A, Cavo M, Bringhen S et al.. “Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21282540 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[107]
Kelly RJ, Hill A, Arnold LM et al.. “Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.” Blood (2011). PMID: 21460245 ↗
L4TRIAL_NONRANDOMCited in: Pharmacodynamics
[108]
Sharman JP, Egyed M, Jurczak W et al.. “Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.” Lancet (London, England) (2020). PMID: 32305093 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[109]
Goette A, Merino JL, Ezekowitz MD et al.. “Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.” Lancet (London, England) (2016). PMID: 27590218 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[110]
Brekelmans MP, Ageno W, Beenen LF et al.. “Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.” The Lancet. Haematology (2016). PMID: 27570090 ↗
L2RCTCited in: Pharmacodynamics, Indications and Clinical Use
[111]
Onundarson PT, Francis CW, Indridason OS et al.. “Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial.” The Lancet. Haematology (2015). PMID: 26688233 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use
[112]
Boonyawat K, Caron F, Li A et al.. “Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28407368 ↗
L1SR_MA_RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose Modification
[113]
Giugliano RP, Ruff CT, Braunwald E et al.. “Edoxaban versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2013). PMID: 24251359 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[114]
Bauersachs R, Berkowitz SD, Brenner B et al.. “Oral rivaroxaban for symptomatic venous thromboembolism.” The New England journal of medicine (2010). PMID: 21128814 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity, Monitoring and Follow-up
[115]
Agnelli G, Buller HR, Cohen A et al.. “Oral apixaban for the treatment of acute venous thromboembolism.” The New England journal of medicine (2013). PMID: 23808982 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[116]
Büller HR, Décousus H, Grosso MA et al.. “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.” The New England journal of medicine (2013). PMID: 23991658 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Adverse Effects and Toxicity
[117]
Saver JL, Carroll JD, Thaler DE et al.. “Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.” The New England journal of medicine (2017). PMID: 28902590 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[118]
Cannon CP, Bhatt DL, Oldgren J et al.. “Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.” The New England journal of medicine (2017). PMID: 28844193 ↗
L1RCTCited in: Pharmacodynamics, Adverse Effects and Toxicity
[119]
Birnie DH, Healey JS, Wells GA et al.. “Pacemaker or defibrillator surgery without interruption of anticoagulation.” The New England journal of medicine (2013). PMID: 23659733 ↗
L1RCTCited in: Pharmacodynamics
[120]
Ruff CT, Giugliano RP, Braunwald E et al.. “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.” Lancet (London, England) (2013). PMID: 24315724 ↗
L1SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[121]
Woller SC, Stevens SM, Kaplan D et al.. “Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial.” Blood advances (2022). PMID: 34662890 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose Modification, Adverse Effects and Toxicity
[122]
Burbury KL, Milner A, Snooks B et al.. “Short-term warfarin reversal for elective surgery--using low-dose intravenous vitamin K: safe, reliable and convenient*.” British journal of haematology (2011). PMID: 21751986 ↗
L4TRIAL_NONRANDOMCited in: Pharmacodynamics, Adverse Effects and Toxicity
[123]
Holmes DR, Reddy VY, Turi ZG et al.. “Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.” Lancet (London, England) (2009). PMID: 19683639 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[124]
Wallentin L, Yusuf S, Ezekowitz MD et al.. “Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.” Lancet (London, England) (2010). PMID: 20801496 ↗
L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Adverse Effects and Toxicity
[125]
Lopes RD, Al-Khatib SM, Wallentin L et al.. “Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.” Lancet (London, England) (2012). PMID: 23036896 ↗
L2RCTCited in: Pharmacodynamics, Indications and Clinical Use
[126]
Büller HR, Gallus AS, Pillion G et al.. “Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.” Lancet (London, England) (2011). PMID: 22130488 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use
[127]
Ruff CT, Giugliano RP, Braunwald E et al.. “Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.” Lancet (London, England) (2015). PMID: 25769361 ↗
L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[128]
Caldeira D, David C, Santos AT et al.. “Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24593838 ↗
L2SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use
[129]
Vidal E, Sharathkumar A, Glover J et al.. “Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24801495 ↗
L2SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity, Special Populations and Contraindications, Monitoring and Follow-up
[130]
Heit JA, Lahr BD, Petterson TM et al.. “Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study.” Blood (2011). PMID: 21890644 ↗
L2COHORTCited in: Pharmacodynamics, Dose and Administration, Dose Modification, Special Populations and Contraindications
[131]
Kampouraki E, Avery PJ, Wynne H et al.. “Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over-anticoagulated patients: a randomised clinical trial.” British journal of haematology (2017). PMID: 28771671 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Dose Modification, Adverse Effects and Toxicity
[132]
Schulman S, Hwang HG, Eikelboom JW et al.. “Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24837794 ↗
L1RCTCited in: Pharmacodynamics
[133]
Christersson C, Wallentin L, Andersson U et al.. “D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24942912 ↗
L2RCTCited in: Pharmacodynamics
[134]
Hosokawa K, Abe K, Funakoshi K et al.. “Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37044277 ↗
L2COHORTCited in: Pharmacodynamics
[135]
Cohen H, Isenberg DA. “How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome.” Blood (2021). PMID: 32898856 ↗
L5OTHERCited in: Pharmacodynamics
[136]
Li C, Schwarz UI, Ritchie MD et al.. “Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.” Blood (2008). PMID: 19074728 ↗
L2OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification
[137]
Moreau C, Bajolle F, Siguret V et al.. “Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.” Blood (2011). PMID: 22130800 ↗
L2OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification, Special Populations and Contraindications
[138]
Kushnir M, Choi Y, Eisenberg R et al.. “Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.” The Lancet. Haematology (2019). PMID: 31133411 ↗
L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
[139]
Resende B, Simões M, Ferraz-Costa G et al.. “Meta-Analysis of Randomised Controlled Trials on the Efficacy of Direct Oral Anticoagulants in Left Ventricular Thrombosis: An Updated Perspective.” Heart, lung & circulation (2026). PMID: 42392916 ↗
L1SR_MA_RCTCited in: Pharmacodynamics
[140]
Chilaka C, Khan HD, Sarfraz MU et al.. “Left Atrial Appendage Closure vs. Oral Anticoagulation in Patients With Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of arrhythmia (2026). PMID: 42328186 ↗
L1SR_MA_RCTCited in: Pharmacodynamics
[141]
Cuttica N, Baumann AN, Yazdanpanah S et al.. “Efficacy of different types of chemoprophylaxis for venous thromboembolism in elective spine surgery: A network meta-analysis of randomized controlled trials.” Journal of orthopaedics (2026). PMID: 41736902 ↗
L1SR_MA_RCTCited in: Pharmacodynamics
[142]
Saraei R, Heine GH, Osmancik P et al.. “Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: Rationale and design of the prospective randomized LAA-KIDNEY trial.” American heart journal (2026). PMID: 42107551 ↗
L5TRIAL_NONRANDOMCited in: Pharmacodynamics
[143]
Wu X, Meng J, Yang Y et al.. “Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.” Renal failure (2026). PMID: 42128628 ↗
L2SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
[144]
Meng M, Xu Q, Qin S et al.. “Efficacy and safety evaluation of thromboprophylaxis strategies for central venous catheter-related thrombosis in cancer patients: a bayesian network meta-analysis and bibliometric analysis.” Frontiers in pharmacology (2026). PMID: 42057843 ↗
L1SR_OBSCited in: Pharmacodynamics
[145]
Zhao J, Chen C, Lu L et al.. “NOACs effects in the secondary prevention of atrial fibrillation-related ischemic stroke/TIA: a systematic review and meta-analysis.” Journal of neurology (2026). PMID: 41632318 ↗
L1SR_OBSCited in: Pharmacodynamics
[146]
Al Said S, Braunwald E, Palazzolo MG et al.. “Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.” Circulation (2026). PMID: 41614257 ↗
L1SR_OBSCited in: Pharmacodynamics
[147]
Li S, Liu S, Liu XR et al.. “Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy.” Blood advances (2020). PMID: 32433747 ↗
L5OTHERCited in: Pharmacodynamics
[148]
Ingason AB, Hreinsson JP, Agustsson AS et al.. “Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study.” Blood advances (2023). PMID: 36562754 ↗
L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
[149]
Naymagon L, Tremblay D, Zubizarreta N et al.. “The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis.” Blood advances (2020). PMID: 32078681 ↗
L2OTHERCited in: Pharmacodynamics
[150]
Ryu J, La J, Patell R et al.. “Survival assessment of warfarin and international normalized ratio exposure in cancer-associated venous thromboembolism: Veterans Affairs healthcare system-based analysis.” Haematologica (2026). PMID: 41924910 ↗
L2OTHERCited in: Pharmacodynamics
[151]
Noble S, Matzdorff A, Maraveyas A et al.. “Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology.” Haematologica (2015). PMID: 26294737 ↗
L4OTHERCited in: Pharmacodynamics
[152]
Zhu YF, Qian H, Ma JH et al.. “Effectiveness and Safety of Aspirin Versus Other Antithrombotics for VTE After Total Hip and Knee Arthroplasty in Real-World Setting.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 41549678 ↗
L2SR_OBSCited in: Pharmacodynamics
[153]
Gameil A, Ghasoub R, Jafari N et al.. “Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.” Oncology (2026). PMID: 41525412 ↗
L2SR_OBSCited in: Pharmacodynamics
[154]
Payne JH. “Aspects of anticoagulation in children.” British journal of haematology (2010). PMID: 20528873 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Adverse Effects and Toxicity, Special Populations and Contraindications, Monitoring and Follow-up
[155]
Arachchillage DRJ, Alavian S, Griffin J et al.. “Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.” British journal of haematology (2018). PMID: 30515764 ↗
L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
[156]
Arachchillage DRJ, Laffan M. “What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?” British journal of haematology (2020). PMID: 32108324 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics
[157]
Czuprynska J, Patel JP, Arya R. “Current challenges and future prospects in oral anticoagulant therapy.” British journal of haematology (2017). PMID: 28573648 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Dose Modification, Adverse Effects and Toxicity, Monitoring and Follow-up
[158]
Baker P, Gleghorn A, Tripp T et al.. “Reversal of asymptomatic over-anticoagulation by orally administered vitamin K.” British journal of haematology (2006). PMID: 16643436 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Dose Modification
[159]
Chang YC, Song J, Chi KY et al.. “The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy.” British journal of haematology (2024). PMID: 38981737 ↗
L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
[160]
Karthikeyan G, Eikelboom JW, Turpie AG et al.. “Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?” British journal of haematology (2009). PMID: 19438502 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics
[161]
Costa TA, Felix N, Richter J. “'X' marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma.” British journal of haematology (2024). PMID: 38986221 ↗
L5OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
[162]
Blombäck M, He S, Bark N et al.. “Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.” British journal of haematology (2011). PMID: 21250974 ↗
L5OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification
[163]
Montes R, Ruiz de Gaona E, Martínez-González MA et al.. “The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.” British journal of haematology (2006). PMID: 16611310 ↗
L4OTHERCited in: Pharmacodynamics, Dose and Administration, Dose Modification
[164]
Cohen H, Efthymiou M, Isenberg DA. “Use of direct oral anticoagulants in antiphospholipid syndrome.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29624847 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics, Adverse Effects and Toxicity
[165]
Kovac M, Ignjatovic V, Orlando C et al.. “The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39233011 ↗
L5REVIEW_NARRATIVECited in: Pharmacodynamics, Adverse Effects and Toxicity
[166]
Rathbun SW, Stoner JA, Whitsett TL. “Treatment of upper-extremity deep vein thrombosis.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21838756 ↗
L2OTHERCited in: Pharmacodynamics, Adverse Effects and Toxicity
[167]
Chao TF, Braunwald E, Palazzolo MG et al.. “Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF.” European heart journal (2026). PMID: 42059513 ↗
L1SR_OBSCited in: Pharmacodynamics
[168]
Skolnick BE, Mathews DR, Khutoryansky NM et al.. “Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.” Blood (2010). PMID: 20385794 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[169]
Lopes RD, Guimarães PO, Kolls BJ et al.. “Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.” Blood (2017). PMID: 28356246 ↗
L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[170]
Garcia D, Alexander JH, Wallentin L et al.. “Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.” Blood (2014). PMID: 25320240 ↗
L2RCTCited in: Indications and Clinical Use
[171]
Kearon C, Julian JA, Kovacs MJ et al.. “Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.” Blood (2008). PMID: 18791166 ↗
L2RCTCited in: Indications and Clinical Use, Dose and Administration, Dose Modification
[172]
Galli M, Borrelli G, Jacobsen EM et al.. “Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.” Blood (2007). PMID: 17440049 ↗
L2RCTCited in: Indications and Clinical Use, Special Populations and Contraindications
[173]
Sconce E, Avery P, Wynne H et al.. “Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.” Blood (2006). PMID: 17110451 ↗
L1RCTCited in: Indications and Clinical Use
[174]
Cohen H, Hunt BJ, Efthymiou M et al.. “Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.” The Lancet. Haematology (2016). PMID: 27570089 ↗
L1RCTCited in: Indications and Clinical Use
[175]
Granger CB, Alexander JH, McMurray JJ et al.. “Apixaban versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2011). PMID: 21870978 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[176]
Patel MR, Mahaffey KW, Garg J et al.. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.” The New England journal of medicine (2011). PMID: 21830957 ↗
L1RCTCited in: Indications and Clinical Use, Dose Modification, Adverse Effects and Toxicity
[177]
Calkins H, Willems S, Gerstenfeld EP et al.. “Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.” The New England journal of medicine (2017). PMID: 28317415 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[178]
Connolly SJ, Ezekowitz MD, Yusuf S et al.. “Dabigatran versus warfarin in patients with atrial fibrillation.” The New England journal of medicine (2009). PMID: 19717844 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[179]
Douketis JD, Spyropoulos AC, Kaatz S et al.. “Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.” The New England journal of medicine (2015). PMID: 26095867 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[180]
Eikelboom JW, Connolly SJ, Brueckmann M et al.. “Dabigatran versus warfarin in patients with mechanical heart valves.” The New England journal of medicine (2013). PMID: 23991661 ↗
L1RCTCited in: Indications and Clinical Use, Dose Modification, Adverse Effects and Toxicity
[181]
Schulman S, Kearon C, Kakkar AK et al.. “Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.” The New England journal of medicine (2013). PMID: 23425163 ↗
L1RCTCited in: Indications and Clinical Use, Monitoring and Follow-up
[182]
Homma S, Thompson JL, Pullicino PM et al.. “Warfarin and aspirin in patients with heart failure and sinus rhythm.” The New England journal of medicine (2012). PMID: 22551105 ↗
L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[183]
Makkar RR, Fontana G, Jilaihawi H et al.. “Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves.” The New England journal of medicine (2015). PMID: 26436963 ↗
L4RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[184]
Starling N, Rao S, Cunningham D et al.. “Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19398575 ↗
L2RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[185]
Khorana AA, Kamphuisen PW, Meyer G et al.. “Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28029329 ↗
L2RCTCited in: Indications and Clinical Use
[186]
Ma L, Hu X, Song L et al.. “The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.” Lancet (London, England) (2023). PMID: 37245517 ↗
L1RCTCited in: Indications and Clinical Use
[187]
Mant J, Hobbs FD, Fletcher K et al.. “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.” Lancet (London, England) (2007). PMID: 17693178 ↗
L1RCTCited in: Indications and Clinical Use
[188]
Young AM, Billingham LJ, Begum G et al.. “Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial.” Lancet (London, England) (2009). PMID: 19217991 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[189]
Warkentin AE, Donadini MP, Spencer FA et al.. “Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22257078 ↗
L1SR_MA_RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[190]
Chai-Adisaksopha C, Hillis C, Isayama T et al.. “Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26356595 ↗
L1SR_MA_RCTCited in: Indications and Clinical Use
[191]
Mahé I, Bertrand N, Drouet L et al.. “Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study.” Haematologica (2006). PMID: 17145598 ↗
L1RCTCited in: Indications and Clinical Use, Drug Interactions
[192]
Couturaud F, Pernod G, Presles E et al.. “Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial.” Haematologica (2019). PMID: 30606789 ↗
L1RCTCited in: Indications and Clinical Use, Dose and Administration
[193]
Asiimwe IG, Blockman M, Cavallari LH et al.. “Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.” Blood advances (2024). PMID: 39163621 ↗
L2SR_OBSCited in: Indications and Clinical Use
[194]
Yoshioka H, Sato H, Hatakeyama H et al.. “Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.” Blood advances (2018). PMID: 29760204 ↗
L1SR_OBSCited in: Indications and Clinical Use
[195]
Bradbury C, Fletcher K, Sun Y et al.. “A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study).” British journal of haematology (2019). PMID: 31713863 ↗
L1RCTCited in: Indications and Clinical Use
[196]
Gardiner C, Williams K, Longair I et al.. “A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing.” British journal of haematology (2006). PMID: 16445833 ↗
L1RCTCited in: Indications and Clinical Use
[197]
Pengo V, Hoxha A, Andreoli L et al.. “Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 33128325 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[198]
Poller L, Jespersen J, Ibrahim S. “Warfarin or dabigatran for treatment of atrial fibrillation.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24766817 ↗
L5RCTCited in: Indications and Clinical Use
[199]
Kamphuisen PW, Lee AYY, Meyer G et al.. “Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29573330 ↗
L2RCTCited in: Indications and Clinical Use, Monitoring and Follow-up
[200]
Ryan F, Byrne S, O'Shea S. “Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19496921 ↗
L1RCTCited in: Indications and Clinical Use
[201]
Heneghan C, Alonso-Coello P, Garcia-Alamino JM et al.. “Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.” Lancet (London, England) (2006). PMID: 16458764 ↗
L1SR_OBSCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[202]
Minhas H, Welsher A, Turcotte M et al.. “Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta-analysis of prospective studies.” British journal of haematology (2018). PMID: 30028001 ↗
L2SR_OBSCited in: Indications and Clinical Use
[203]
Saokaew S, Permsuwan U, Chaiyakunapruk N et al.. “Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20831620 ↗
L2SR_OBSCited in: Indications and Clinical Use
[204]
Wolfe Z, Khan SU, Nasir F et al.. “A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29723935 ↗
L1SR_OBSCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[205]
Melkonian M, Jarzebowski W, Pautas E et al.. “Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28393461 ↗
L1SR_OBSCited in: Indications and Clinical Use
[206]
Liew A, O'Donnell M, Douketis J. “Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24986568 ↗
L1SR_OBSCited in: Indications and Clinical Use
[207]
Costa TA, Chagas GCL, Tavares de Sousa LM et al.. “Efficacy and safety of direct oral anticoagulants versus warfarin in patients with a left ventricular thrombus: an updated systematic review and meta-analysis of randomised controlled trials.” Open heart (2025). PMID: 41265923 ↗
L1SR_MA_RCTCited in: Indications and Clinical Use
[208]
Wang C, Luo J, Zhou X et al.. “Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial.” BMJ open (2026). PMID: 41663175 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity, Monitoring and Follow-up
[209]
Liang M, Jin J, Zhao R et al.. “Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI).” BMC medicine (2025). PMID: 41254594 ↗
L1RCTCited in: Indications and Clinical Use
[210]
Gao TM, Xiao KQ, Zhou LX et al.. “Comparison of apixaban and warfarin in preventing portal vein system thrombosis after laparoscopic splenectomy for cirrhotic patients with secondary hypersplenism: a randomized controlled trial.” Surgical endoscopy (2025). PMID: 41131381 ↗
L1RCTCited in: Indications and Clinical Use
[211]
Ren X, Li Q, Ouyang M et al.. “Mediation Analysis to Identify Individual Component Effects of the Care Bundle to Improve Functional Outcome After ICH in the INTERACT3 Study.” Neurology (2025). PMID: 40939125 ↗
L1RCTCited in: Indications and Clinical Use
[212]
Mehta A, Bagchi P, Looby M et al.. “Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025). PMID: 40819750 ↗
L1RCTCited in: Indications and Clinical Use, Dose Modification
[213]
Nicolau AM, Giugliano RP, Zimerman A et al.. “Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.” Journal of the American College of Cardiology (2025). PMID: 40769671 ↗
L1RCTCited in: Indications and Clinical Use
[214]
Stone P, Minton O, Richardson A et al.. “Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial.” Health technology assessment (Winchester, England) (2025). PMID: 40755226 ↗
L1RCTCited in: Indications and Clinical Use
[215]
Moonsamy P, Zhao Y, Makarem A et al.. “Randomized Controlled: Trial of New Oral Anticoagulants Versus Warfarin for Postcardiac Surgery Atrial Fibrillation: The NEW-AF Trial.” Annals of surgery (2025). PMID: 40704706 ↗
L1RCTCited in: Indications and Clinical Use
[216]
Izumi C, Amano M, Yoshikawa Y et al.. “Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial.” Circulation. Cardiovascular interventions (2025). PMID: 40663622 ↗
L1RCTCited in: Indications and Clinical Use
[217]
Parker WAE, Nelson TA, Lee J et al.. “Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial.” European heart journal (2026). PMID: 40444814 ↗
L2RCTCited in: Indications and Clinical Use
[218]
Qian Y, Chen W, Zhou B et al.. “Efficacy, Safety, and Cost-Effectiveness of "Internet + Pharmacy Care" Via the Alfalfa App in Warfarin Therapy Management After Cardiac Valve Replacement: Randomized Controlled Trial.” JMIR mHealth and uHealth (2025). PMID: 40393057 ↗
L1RCTCited in: Indications and Clinical Use, Dose Modification
[219]
Dangas GD, Unverdorben M, Nicolas J et al.. “Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial.” Journal of the American Heart Association (2025). PMID: 40371611 ↗
L1RCTCited in: Indications and Clinical Use, Dose Modification
[220]
Kurlander JE, Helminski D, Tao X et al.. “An Intervention to Reduce Antiplatelet Use without Gastroprotection in Patients Using Warfarin: The AEGIS Cluster Randomized Trial.” Thrombosis and haemostasis (2025). PMID: 40315868 ↗
L1RCTCited in: Indications and Clinical Use
[221]
Chairat P, Niprapan P, Hantrakun N et al.. “Randomized controlled trial evaluating the benefit of the app-based clinical decision support system for the management of venous thromboembolism.” BMC medical education (2025). PMID: 40159474 ↗
L1RCTCited in: Indications and Clinical Use
[222]
Semco RS, Bergmark RW, Murphy SA et al.. “Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial.” Journal of the American Heart Association (2025). PMID: 39791401 ↗
L1RCTCited in: Indications and Clinical Use
[223]
Ruel M, Chu MWA, Graeve A et al.. “Midterm survival, clinical, and hemodynamic outcomes of a novel mechanical mitral valve prosthesis.” The Journal of thoracic and cardiovascular surgery (2024). PMID: 39617318 ↗
L1RCTCited in: Indications and Clinical Use
[224]
Lip GY, Halperin JL, Petersen P et al.. “A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26052866 ↗
L1RCTCited in: Dose and Administration
[225]
Shrivastava S, Ridker PM, Glynn RJ et al.. “D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2006). PMID: 16706961 ↗
L1RCTCited in: Dose and Administration
[226]
Buller HR, Halperin J, Hankey GJ et al.. “Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24597472 ↗
L1RCTCited in: Dose and Administration, Dose Modification
[227]
Lassen MR, Davidson BL, Gallus A et al.. “The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17868430 ↗
L1RCTCited in: Dose and Administration, Dose Modification
[228]
Raskob G, Büller H, Prins M et al.. “Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23574579 ↗
L5RCTCited in: Dose and Administration
[229]
Lund K, Gaffney D, Spooner R et al.. “Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.” British journal of haematology (2012). PMID: 22571356 ↗
L2TRIAL_NONRANDOMCited in: Dose and Administration, Adverse Effects and Toxicity, Monitoring and Follow-up
[230]
Holm J, Lindh JD, Andersson ML et al.. “The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28058824 ↗
L3COHORTCited in: Dose and Administration, Dose Modification, Monitoring and Follow-up
[231]
Mannheimer B, Andersson ML, Järnbert-Pettersson H et al.. “The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 26792124 ↗
L3COHORTCited in: Dose and Administration, Drug Interactions
[232]
Ruell J, Smith A, Perera T et al.. “The role of a specialist bridging service. A New Zealand prospective study of 600 patients.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31215756 ↗
L4COHORTCited in: Dose and Administration, Special Populations and Contraindications
[233]
Zimerman A, Braunwald E, Steffel J et al.. “Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.” JAMA cardiology (2024). PMID: 38985461 ↗
L2RCTCited in: Dose and Administration, Dose Modification
[234]
Shu L, Jack N, de Havenon A et al.. “Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2024). PMID: 38944363 ↗
L2RCTCited in: Dose and Administration
[235]
Xue L, Ma G, Holford N et al.. “A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization.” Clinical pharmacology and therapeutics (2024). PMID: 38439157 ↗
L1RCTCited in: Dose and Administration, Dose Modification, Monitoring and Follow-up
[236]
Steffel J, Ruff CT, Yin O et al.. “Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.” Journal of the American College of Cardiology (2021). PMID: 33663737 ↗
L1RCTCited in: Dose and Administration
[237]
Wilkinson C, Wu J, Searle SD et al.. “Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.” BMC medicine (2020). PMID: 33357217 ↗
L2RCTCited in: Dose and Administration
[238]
Biss TT, Avery PJ, Brandão LR et al.. “VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.” Blood (2011). PMID: 22010099 ↗
L4OTHERCited in: Dose and Administration, Dose Modification, Special Populations and Contraindications
[239]
Zhang RF, Ma CM, Wang N et al.. “Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.” BMC cardiovascular disorders (2021). PMID: 33906609 ↗
L2RCTCited in: Dose and Administration
[240]
Zhang H, Li M, Ao XL et al.. “Randomized, placebo-controlled trial of orally administered vitamin K1 for warfarin-associated coagulopathy in Chinese patients with mechanical heart valves.” European journal of clinical pharmacology (2021). PMID: 33783553 ↗
L1RCTCited in: Dose and Administration
[241]
Ning X, Kuang Y, Yang G et al.. “Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial.” Naunyn-Schmiedeberg's archives of pharmacology (2021). PMID: 33404689 ↗
L2RCTCited in: Dose and Administration
[242]
Suwanawiboon B, Rotchanapanya W, Mahaprom K et al.. “The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial.” Hematology (Amsterdam, Netherlands) (2022). PMID: 35068386 ↗
L1RCTCited in: Dose and Administration
[243]
Toomey JR, Abboud MA, Valocik RE et al.. “A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.” Journal of thrombosis and haemostasis : JTH (2006). PMID: 16961606 ↗
L5OTHERCited in: Dose and Administration, Dose Modification
[244]
Le Gal G, Carrier M, Tierney S et al.. “Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19874475 ↗
L3OTHERCited in: Dose and Administration
[245]
Hurtado FK, de Braud F, De Castro Carpeño J et al.. “Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.” Cancer chemotherapy and pharmacology (2021). PMID: 33394101 ↗
L4TRIAL_NONRANDOMCited in: Dose and Administration
[246]
El Rouby N, Shahin MH, Bader L et al.. “Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations.” Clinical and translational science (2021). PMID: 34729928 ↗
L4SR_OBSCited in: Dose and Administration
[247]
Huang W, Sun H, Zhou L et al.. “Application of Loading Dose Warfarin in Postpartum Women with Pulmonary Embolism - a Prospective, Randomized, Double-Blind Trial.” Drug design, development and therapy (2025). PMID: 41321667 ↗
L1RCTCited in: Dose and Administration
[248]
Menon N, Sarode R, Zia A. “Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.” Blood advances (2018). PMID: 29365322 ↗
L4CASE_REPORTCited in: Dose Modification, Adverse Effects and Toxicity
[249]
Ortel TL. “Perioperative management of patients on chronic antithrombotic therapy.” Blood (2012). PMID: 22855600 ↗
L5REVIEW_NARRATIVECited in: Dose Modification, Adverse Effects and Toxicity
[250]
Zhou Q, Wang Z, Wang H et al.. “Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2023). PMID: 36622539 ↗
L4TRIAL_NONRANDOMCited in: Dose Modification
[251]
Pilc E, Bankuru SV, Brauer SF et al.. “Which Interventions Are Effective in Treating Sleep Disturbances After THA or TKA? A Systematic Review.” Clinical orthopaedics and related research (2024). PMID: 39255465 ↗
L5SR_OBSCited in: Dose Modification
[252]
Yang Z, Wang J, Yuan Y et al.. “Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2023). PMID: 36844734 ↗
L1SR_OBSCited in: Dose Modification
[253]
Tham D, Zhao L, Yu W et al.. “Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis.” Research and practice in thrombosis and haemostasis (2024). PMID: 39568775 ↗
L2SR_OBSCited in: Dose Modification
[254]
Larsen TB, Skjøth F, Kjældgaard JN et al.. “Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.” The Lancet. Haematology (2017). PMID: 28411120 ↗
L2COHORTCited in: Adverse Effects and Toxicity
[255]
Bouillon K, Bertrand M, Maura G et al.. “Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.” The Lancet. Haematology (2015). PMID: 26687957 ↗
L2COHORTCited in: Adverse Effects and Toxicity
[256]
Keeling D, Davidson S, Watson H. “The management of heparin-induced thrombocytopenia.” British journal of haematology (2006). PMID: 16643427 ↗
L1GUIDELINECited in: Adverse Effects and Toxicity
[257]
Afzal A, Gage BF, Suhong L et al.. “Different risks of hemorrhage in patients with elevated international normalized ratio from chronic liver disease versus warfarin therapy, a population-based retrospective cohort study.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35491428 ↗
L2COHORTCited in: Adverse Effects and Toxicity
[258]
Green L, Tan J, Morris JK et al.. “A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study).” Haematologica (2018). PMID: 29371325 ↗
L2TRIAL_NONRANDOMCited in: Adverse Effects and Toxicity
[259]
Gailani D, Gruber A. “Targeting factor XI and factor XIa to prevent thrombosis.” Blood (2024). PMID: 38142404 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity, Monitoring and Follow-up
[260]
Schmidt RA, Lee AYY. “How I treat and prevent venous thrombotic complications in patients with lymphoma.” Blood (2022). PMID: 34479364 ↗
L5OTHERCited in: Adverse Effects and Toxicity
[261]
Chan NC, Eikelboom JW. “How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism.” Blood (2019). PMID: 30926593 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
[262]
Goodnough LT, Shander A. “How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage.” Blood (2011). PMID: 21411756 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
[263]
Khorana AA. “The wacky hypercoagulable state of malignancy.” Blood (2015). PMID: 26206943 ↗
L5OTHERCited in: Adverse Effects and Toxicity
[264]
Chen X, Li C, Jin DY et al.. “A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.” Blood (2020). PMID: 32374827 ↗
L5OTHERCited in: Adverse Effects and Toxicity
[265]
Oskarsdottir AR, Gudmundsdottir BR, Jensdottir HM et al.. “Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.” Blood (2021). PMID: 33512454 ↗
L2OTHERCited in: Adverse Effects and Toxicity, Monitoring and Follow-up
[266]
Quintás-Cardama A, Han X, Kantarjian H et al.. “Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.” Blood (2009). PMID: 19414863 ↗
L4OTHERCited in: Adverse Effects and Toxicity
[267]
Zhang H, Löwenberg EC, Crosby JR et al.. “Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.” Blood (2010). PMID: 20807891 ↗
L5OTHERCited in: Adverse Effects and Toxicity
[268]
Kelkar AH, Smith NA, Martial A et al.. “An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois.” The New England journal of medicine (2018). PMID: 30280655 ↗
L4OTHERCited in: Adverse Effects and Toxicity
[269]
Bell C, Afzal A, Carlin S et al.. “Prevention and treatment of thrombosis in patients with decompensated cirrhosis.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41520803 ↗
L5CASE_REPORTCited in: Adverse Effects and Toxicity
[270]
Sakusic A, Ghozy S, Verma Y et al.. “Resumption of Warfarin After Intracranial Hemorrhage in Patients With Mechanical Heart Valves: A Systematic Review and Meta-Analysis.” Journal of the American Heart Association (2026). PMID: 41823243 ↗
L2SR_OBSCited in: Adverse Effects and Toxicity
[271]
Paquette M, Miranda S, Xu Y et al.. “Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome.” Blood advances (2026). PMID: 41843780 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[272]
Ma S, Chang YC, Chiang CH et al.. “Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism.” Blood advances (2026). PMID: 40845270 ↗
L2OTHERCited in: Adverse Effects and Toxicity, Monitoring and Follow-up
[273]
Weycker D, Wygant GD, Guo JD et al.. “Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.” Blood advances (2020). PMID: 31990332 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[274]
Dawwas GK, Cuker A, Lewis JD. “Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism.” Blood advances (2026). PMID: 41191527 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[275]
Shah S, Norby FL, Datta YH et al.. “Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.” Blood advances (2018). PMID: 29378726 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[276]
Hanni C, Petrovitch E, Ali M et al.. “Outcomes associated with apixaban vs warfarin in patients with renal dysfunction.” Blood advances (2020). PMID: 32463871 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[277]
Dawwas GK, Cuker A, Schaubel DE et al.. “Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease.” Blood advances (2024). PMID: 38163322 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[278]
Leader A, Hamulyák EN, Carney BJ et al.. “Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.” Blood advances (2020). PMID: 33351124 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[279]
Alomairi AA, Alduhaysh R, Samandar A et al.. “Cerebrovascular and Bleeding Outcomes of Warfarin versus Direct Oral Anticoagulants Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Neurosciences (Riyadh, Saudi Arabia) (2026). PMID: 42415975 ↗
L1SR_MA_RCTCited in: Adverse Effects and Toxicity
[280]
Lip GY, Tse HF, Lane DA. “Atrial fibrillation.” Lancet (London, England) (2011). PMID: 22166900 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
[281]
Chakravarty T, Søndergaard L, Friedman J et al.. “Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study.” Lancet (London, England) (2017). PMID: 28330690 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[282]
Zwicker JI, Paranagama D, Lessen DS et al.. “Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.” Haematologica (2022). PMID: 34162181 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[283]
Krauth MT, Lechner K, Neugebauer EA et al.. “The postoperative splenic/portal vein thrombosis after splenectomy and its prevention--an unresolved issue.” Haematologica (2008). PMID: 18556406 ↗
L5OTHERCited in: Adverse Effects and Toxicity
[284]
Liu E, Tilbury N, Morin T et al.. “Antiplatelet and Anticoagulation Use and Outcomes Following Chronic Subdural Hematoma Drainage: Systematic Review and Meta-analysis.” World neurosurgery (2026). PMID: 41707892 ↗
L1SR_OBSCited in: Adverse Effects and Toxicity
[285]
Scully M, Gates C, Neave L. “How we manage patients with heparin induced thrombocytopenia.” British journal of haematology (2016). PMID: 27097741 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
[286]
Parker K, Mitra S, Thachil J. “Is anticoagulating haemodialysis patients with non-valvular atrial fibrillation too risky?” British journal of haematology (2018). PMID: 29468649 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
[287]
Pastori D, Lip GYH, Poli D et al.. “Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study.” British journal of haematology (2020). PMID: 32080833 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[288]
Wheeler DS, Giugliano RP, Rangaswami J. “Anticoagulation-related nephropathy.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 26670286 ↗
L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
[289]
Dawwas GK, Cuker A. “Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39442621 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[290]
Lee J, Kong X, Haymart B et al.. “Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35962753 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[291]
Youssef E, Daher M, Milad A et al.. “Is dabigatran a good alternative to warfarin in patients with atrial fibrillation accompanied by valvular and non-valvular heart diseases? A systematic review and meta-analysis.” La Tunisie medicale (2025). PMID: 41879686 ↗
L1SR_OBSCited in: Adverse Effects and Toxicity
[292]
Tuo M, Li Y, Shi Z et al.. “Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.” Frontiers in immunology (2026). PMID: 42358967 ↗
L4CASE_REPORTCited in: Adverse Effects and Toxicity
[293]
Kim D, Jo S, Hwang I et al.. “Association of anticoagulant and antiplatelet therapy with acute cerebral infarction in patients presenting with isolated vertigo or dizziness: A retrospective cohort study.” PloS one (2026). PMID: 42275463 ↗
L2COHORTCited in: Adverse Effects and Toxicity
[294]
Theivendran T, Vucak-Dzumhur M, Lee VW et al.. “Topical Sodium Thiosulfate for the Treatment of Calciphylaxis: Case Report.” Nephrology (Carlton, Vic.) (2026). PMID: 42104624 ↗
L4CASE_REPORTCited in: Adverse Effects and Toxicity
[295]
Menichelli D, Cormaci VMD, Gazzaniga G et al.. “Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.” Cancer (2026). PMID: 42411384 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[296]
Crowley B, Hollimon M, Joaquin T et al.. “The Impact of Anticoagulant Choice on Rates of Manipulation Under Anesthesia, Hematoma Formation, and Venous Thromboembolic Events.” The Journal of arthroplasty (2026). PMID: 42373147 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[297]
Shoji S, Gouda P, Falvey CA et al.. “Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.” NEJM evidence (2026). PMID: 42187550 ↗
L1OTHERCited in: Adverse Effects and Toxicity
[298]
Anan K, Itaya T, Kataoka Y et al.. “Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case-Crossover Study Using Japanese Administrative Data.” Pharmacoepidemiology and drug safety (2026). PMID: 42175652 ↗
L3OTHERCited in: Adverse Effects and Toxicity
[299]
Gouda P, Harrington J, Arps K et al.. “Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practice.” American heart journal (2026). PMID: 42162604 ↗
L2OTHERCited in: Adverse Effects and Toxicity
[300]
Kategeaw W, Witt DM, King JB et al.. “Cost-Effectiveness Analysis of Patient Self-Management of Warfarin Among Patients With Non-Valvular Atrial Fibrillation.” Pharmacotherapy (2026). PMID: 42136139 ↗
L5OTHERCited in: Adverse Effects and Toxicity
[301]
Vazquez SR. “Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.” Blood (2018). PMID: 30463993 ↗
L5REVIEW_NARRATIVECited in: Drug Interactions
[302]
Verheugt FW, Granger CB. “Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.” Lancet (London, England) (2015). PMID: 25777666 ↗
L5REVIEW_NARRATIVECited in: Drug Interactions
[303]
Galliazzo S, Bucciarelli P, Barcellona D et al.. “Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.” Thrombosis and haemostasis (2024). PMID: 38626900 ↗
L5GUIDELINECited in: Drug Interactions, Monitoring and Follow-up
[304]
Cabral KP, Ansell J, Hylek EM. “Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21176102 ↗
L5REVIEW_NARRATIVECited in: Drug Interactions
[305]
Nguyen AT, Tepper NK, Gold H et al.. “Safety of contraception among women using anticoagulant therapy: An updated systematic review.” Contraception (2025). PMID: 41177211 ↗
L2SR_OBSCited in: Drug Interactions
[306]
Ho JJY, Goh C, Leong CSA et al.. “Evaluation of potential drug-drug interactions with medical cannabis.” Clinical and translational science (2024). PMID: 38720531 ↗
L2SR_OBSCited in: Drug Interactions
[307]
Calvarysky B, Dotan I, Shepshelovich D et al.. “Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.” Drug safety (2024). PMID: 38273155 ↗
L1SR_OBSCited in: Drug Interactions
[308]
Smythe MA, Wu W, Garwood CL. “Anticoagulant drug-drug interactions with cannabinoids: A systematic review.” Pharmacotherapy (2023). PMID: 37740600 ↗
L2SR_OBSCited in: Drug Interactions
[309]
Hughes JE, Waldron C, Bennett KE et al.. “Prevalence of Drug-Drug Interactions in Older Community-Dwelling Individuals: A Systematic Review and Meta-analysis.” Drugs & aging (2023). PMID: 36692678 ↗
L1SR_OBSCited in: Drug Interactions
[310]
Iversen DB, Dunvald AD, Jespersen DM et al.. “Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes.” Clinical pharmacology and therapeutics (2023). PMID: 37235733 ↗
L1RCTCited in: Drug Interactions
[311]
Wood MD, Delate T, Clark M et al.. “An evaluation of the potential drug interaction between warfarin and levothyroxine.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24913218 ↗
L3OTHERCited in: Drug Interactions
[312]
Smith SA, Morrissey JH. “Polyphosphate as a general procoagulant agent.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18665922 ↗
L5OTHERCited in: Drug Interactions
[313]
Wijnen JC, van de Riet IR, Lijfering WM et al.. “Metformin use decreases the anticoagulant effect of phenprocoumon.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 24698366 ↗
L3OTHERCited in: Drug Interactions
[314]
Stage TB, Pottegård A, Henriksen DP et al.. “Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26559049 ↗
L3OTHERCited in: Drug Interactions
[315]
Bérété ZC, Sebgo AA, Eurich DT et al.. “Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study.” Age and ageing (2025). PMID: 41396801 ↗
L2COHORTCited in: Drug Interactions
[316]
Witmer C, Raffini L. “Treatment of venous thromboembolism in pediatric patients.” Blood (2020). PMID: 31917400 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
[317]
Kamat AV, D'Cruz DP, Hunt BJ. “Managing antiphospholipid antibodies and antiphospholipid syndrome in children.” Haematologica (2006). PMID: 17145604 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
[318]
Arachchillage DRJ, Laffan M. “Pathogenesis and management of antiphospholipid syndrome.” British journal of haematology (2017). PMID: 28339096 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
[319]
Cohen H, Efthymiou M, Devreese KMJ. “Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33325604 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
[320]
Nowak-Göttl U, Dietrich K, Schaffranek D et al.. “In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.” Blood (2010). PMID: 20833980 ↗
L2OTHERCited in: Special Populations and Contraindications
[321]
Li HY, Wang J, Wang T et al.. “Management of venous thromboembolism in pediatric patients: Quality assessment of clinical practice guidelines and variations in recommendations.” Thrombosis research (2023). PMID: 37141795 ↗
L5GUIDELINECited in: Special Populations and Contraindications
[322]
Furlan A, Vianello F, Clementi M et al.. “Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report.” Haematologica (2006). PMID: 16923524 ↗
L4CASE_REPORTCited in: Special Populations and Contraindications
[323]
Iancu A, Leb I, Prokosch HU et al.. “Machine learning in medication prescription: A systematic review.” International journal of medical informatics (2023). PMID: 37939541 ↗
L2SR_OBSCited in: Special Populations and Contraindications
[324]
Shishesaz MI, Eshraghi R, Bahrami A et al.. “The effectiveness and side effects of anti-coagulant drugs in pregnant women with mechanical or bio-prosthetic heart valves: A systematic review and meta-analysis study.” Journal of cardiology (2025). PMID: 40816699 ↗
L1SR_OBSCited in: Special Populations and Contraindications
[325]
Assempoor R, Abroy AS, Azarboo A et al.. “Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis.” BMC pediatrics (2024). PMID: 39548432 ↗
L1SR_OBSCited in: Special Populations and Contraindications
[326]
Zhang Z, Zhou J, Lin Q et al.. “Overcoming barriers for left atrial appendage thrombus: a systematic review of left atrial appendage closure.” BMC cardiovascular disorders (2024). PMID: 38515032 ↗
L2SR_OBSCited in: Special Populations and Contraindications
[327]
DeSancho MT, Suvar E, Roberts JC et al.. “Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39151704 ↗
L2OTHERCited in: Special Populations and Contraindications
[328]
Neuman YP, Sawaid K, Cohen O et al.. “Age-Specific Differences in Cerebral Sinus Venous Thrombosis: A Retrospective Cohort Study From a Tertiary Care Center.” Pediatric blood & cancer (2025). PMID: 40734251 ↗
L2COHORTCited in: Special Populations and Contraindications
[329]
Tan H, Zhang X, Wang W et al.. “Percutaneous Transluminal Angioplasty Alleviate Pediatric Postthrombotic Syndrome: A Case Report and Literature Review.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2024). PMID: 39086107 ↗
L4CASE_REPORTCited in: Special Populations and Contraindications
[330]
Federspiel JJ, Rodger MA, Hoffman MR et al.. “Postoperative venous thromboembolism following cesarean delivery: prevalence, pathophysiology, diagnosis, treatment, and prevention.” American journal of obstetrics and gynecology (2026). PMID: 41485833 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
[331]
Mittal P, Sayar Z, Cohen H. “Warfarin and heparin monitoring in antiphospholipid syndrome.” Hematology. American Society of Hematology. Education Program (2024). PMID: 39644000 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Contraindications, Monitoring and Follow-up
[332]
Schulman S, Kearon C, Kakkar AK et al.. “Dabigatran versus warfarin in the treatment of acute venous thromboembolism.” The New England journal of medicine (2009). PMID: 19966341 ↗
L1RCTCited in: Monitoring and Follow-up
[333]
Matchar DB, Jacobson A, Dolor R et al.. “Effect of home testing of international normalized ratio on clinical events.” The New England journal of medicine (2010). PMID: 20961244 ↗
L1RCTCited in: Monitoring and Follow-up
[334]
Jonsson PI, Letertre L, Juliusson SJ et al.. “During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 27774726 ↗
L2RCTCited in: Monitoring and Follow-up
[335]
Ferder NS, Eby CS, Deych E et al.. “Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19874474 ↗
L2RCTCited in: Monitoring and Follow-up
[336]
Witt DM, Delate T, Clark NP et al.. “Outcomes and predictors of very stable INR control during chronic anticoagulation therapy.” Blood (2009). PMID: 19439733 ↗
L2OTHERCited in: Monitoring and Follow-up
[337]
Budnitz DS, Lovegrove MC, Shehab N et al.. “Emergency hospitalizations for adverse drug events in older Americans.” The New England journal of medicine (2011). PMID: 22111719 ↗
L2OTHERCited in: Monitoring and Follow-up
[338]
Kontopodis N, Galanakis N, Ioannou CV et al.. “Systematic Review and Meta-Analysis of the Effect of Anticoagulation on Outcomes After Endovascular Aneurysm Repair.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023). PMID: 38031419 ↗
L2SR_OBSCited in: Monitoring and Follow-up
[339]
Gopalakrishnan C, Schneeweiss S, Bartels DB et al.. “Evaluating utilization patterns of oral anticoagulants in routine care.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31038824 ↗
L2OTHERCited in: Monitoring and Follow-up
[340]
Chiasakul T, Redd R, Patell R et al.. “Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34490999 ↗
L2OTHERCited in: Monitoring and Follow-up
[341]
Mao T, Xia X, Ma R. “Pharmacist-Led Genotype-Guided Warfarin Therapy in Valve Replacement: An Observation Cohort Study.” The Journal of surgical research (2025). PMID: 40816100 ↗
L2COHORTCited in: Monitoring and Follow-up
[342]
Namjouyan K, Hassan Virk HU, Rizwan A et al.. “Left atrial appendage closure devices: a contemporary review of techniques, tips and tricks.” Frontiers in cardiovascular medicine (2026). PMID: 42064858 ↗
L5REVIEW_NARRATIVECited in: Monitoring and Follow-up

Quick Reference

Overview and Recommendations

Key Facts

Clinical Use

Safety

Board Review — High Yield

Deep Dive — Evidence Details

Introduction and Chemical Structure

Also Called

Chemical Identity

History and Clinical Context

Mechanism of Action

Onset and Time Course

Duration of Action

Stereoselectivity

Resistance and Pharmacogenomics

Key Genetic Variants Influencing Warfarin Dose

Warfarin Resistance (Pharmacodynamic)

Pharmacogenomics‑Guided Dosing: Clinical Evidence and Controversies

Controversies and Guideline Disagreement

Pharmacokinetics (LADME)

Absorption

Distribution

Metabolism

Excretion

Special Populations and PK Variability

Pharmacokinetic Summary Table

Pharmacodynamics

Time Course of Anticoagulation and Factor Suppression

Inhibitory Kinetics and Potency

Clinical Implications of the Pharmacodynamic Profile

Indications and Clinical Use

Approved Indications

Off-Label and Specialized Uses

Positioning Among Anticoagulants

Dose and Administration

Initial Dosing

Target INR Ranges

Pharmacogenetics-Guided Dosing

Special Populations

Management of Over-Anticoagulation

Dose Modification

Renal and Hepatic Impairment

Age and Body Weight

Drug Interactions

Management of Over-Anticoagulation

Perioperative Management

Adverse Effects and Toxicity

Hemorrhage

Tissue Necrosis and Calciphylaxis

Other Adverse Effects

Anticoagulation-Related Nephropathy

Bleeding Risk in Special Populations

Drug Interactions

Pharmacodynamic Interactions

Pharmacokinetic Interactions

Specific High-Impact Interactions

Special Populations and Contraindications

Contraindications

Pregnancy

Pediatrics

Elderly

Immunocompromised and Comorbidities

Monitoring and Follow-up

Baseline Assessment

INR Monitoring Frequency and Targets

Time in Therapeutic Range (TTR)

Self-Testing and Pharmacist-Led Models

Pharmacogenomic-Guided Dosing

Alternative Monitoring: Fiix-Prothrombin Time

Long-Term Follow-Up and Adherence

Special Monitoring Situations

References

of Over-Anticoagulation

of Over-Anticoagulation

Tissue Necrosis and